European Neuropsychopharmacology (v.19, #S3)

P.3.c.044 Use of concomitant medication in the treatment of schizophrenia by F. Oosthuizen; J.B. Bodenstein; R. Reddy (S535-S536).

P.3.c.046 Long-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophrenia by H. Meltzer; M. Cohen; L. Snow-Adami; M. Mackle; J. Zhao; A. Szegedi; J. Panagides (S536-S537).

P.3.c.048 Attitudes concerning depot medication in the German general population: a representative telephone survey by J. Cordes; J. Thuenker; K. Hueckelheim; U. Müller; J. Kornischka (S538).

P.3.c.047 Obesity and antipsychotics drugs in patients with schizophrenia by D.G. Gugleta Dragoslava; S.V. Slavkovic Violeta; T.S. Tosic Golubovic Suzana; S.D. Stankovic Jankovic Dora (S537).

P.3.c.036 Dose pattern and effectiveness of paliperidone in patients with schizophrenia by J-S. Lee; J. Ahn; J. Lee; J. Kim; I. Jung; C. Lee; J. Lee; S. Lee; C. Kim (S530-S531).

P.3.c.038 Adjunctive mood stabilising treatment: the effects on hostility and impulsivity among patients with schizophrenia by S.T. Tosic Golubovic Suzana; Z.O. Zikic Olivera; N.G. Nikolic Gordana; S.V. Slavkovic Violeta; G.D. Gugleta Dragoslava; S.V. Sibinovic Vladica (S532).

P.3.c.040 Predictors for treatment response in patients with acute schizophrenia by A. Schreiner; M. Blanc; L. Bidzan; D. Hoeben; G. Badescu; M. Schmauss; M. Kotler (S533).

P.3.c.049 Short-term improvement by minocycline added to olanzapine antipsychotic treatment in schizophrenia by J. Hallak; C. Chaves; C. Marque; J. Crippa; I. Chaudhry; N. Husain; L. Wichert-Ana; J. Deakhi; A. Zuardi; S. Dursun (S538-S539).

P.3.c.050 Expression of the inflammatory cytokine mRNA in patients with schizophrenia treated with quetiapine by S. Kawashige; H. Kikuyama; A. Tsutsumi; T. Kanazawa; T. Hori; M. Nishiguchi; A. Hokyo; J. Koh; H. Yoneda (S539).

P.3.c.060 Changes in hyperprolactinaemia and related adverse events after switching antipsychotic treatment to quetiapine by A.L. Montejo; S. Majadas; M. Franco; N. Prieto; P. Álvarez; R. Gordo; X.A. Espina; T. Martín; J. Guijarro; G. Medina (S544-S545).

P.3.c.059 Association between antipsychotic treatment and clinical and economic outcomes in schizophrenia and bipolar disorder by M. Mychaskiw; K. Sanders; J. Alvir; L. Montejano; G. Lenhart; C. O'Gorman (S544).

P.3.c.064 Effects of olanzapine and ziprasidone on cognitve outcome in recent-onset schizophrenia by K. Grootens; N.M.J. van Veelen; M.M. Sitskoorn; R.J. Verkes; R.S. Kahn (S547).

P.3.c.063 Effect of 5-HT1a and catechol-O-methyl-transferase gene polymorphisms on negative symptom response to clozapine by S. Porcelli; M. Bosia; F. Cocchi; E. Marino; E. Smeraldi; R. Cavallaro (S546-S547).

P.3.c.055 Paliperidone-induced obsessive compulsive symptoms by E. Tzavellas; T. Paparrigopoulos; D. Karaiskos; R. Zaloni; X. Stachtea; J. Liappas (S542).

P.3.c.034 Eufest: the moderating impact of metabolic co-morbidities on treatment outcomes in first-episode schizophrenia by W. Fleischhacker; R. Kahn; O. Karayal; C. Siu; E. Pappadopulos (S529-S530).

P.3.c.014 Effects of long-acting injectable risperidone on cognitive function in patients with schizophrenia by S.W. Kim; Y.H. Lee; J.H. Lee; K.H. Chung; J.A. Yoo; J.H. Ryu; J.S. Yoon; J.M. Kim; I.S. Shin; S.J. Yang (S518).

P.3.c.017 Performance of the Spanish version of the TOOL questionnaire: impact of adverse events of antipsychotics on patients by A.L. Montejo; J. Correas Lauffer; J. Cuervo; L. Cordero; T. Diez; J. Maurino (S520).

P.3.c.007 Efficacy of atypical antipsychotics in chronic daily headache by N. Kouroumalos; M. Foutouli; K. Kalamafkianaki; E. Nikolakaki (S514-S515).

P.3.c.009 Positive and negative symptoms reduction follow-up in patients treated with olanzapine by M. Krzystanek; E. Krzystanek; I. Krupka-Matuszczyk (S515-S516).

P.3.c.018 Add on of another antipsychotic vs switch to a different antipsychotic: effect on QTc interval by G. di Sciascio; S. Calo; G. Amodio; S. D'Onofrio; R. Pollice (S520-S521).

P.3.c.019 Coronary heart disease risk in schizophrenic patients by J. Castaño; B. Diaz; C. Gamier; A. Navarro; P. Alvaro; R. Sanchis; H. Schroder; L.M. Martin; A. Bulbena (S521-S522).

P.3.c.027 Therapeutic adherence and readmissions in schizophrenic patients treated with paliperidone a 6-month follow-up by J.A. Blanco; J.A. Aguado; G. Medina; O. Segurado; J.I. Franch; J.J. Madrigal (S526).

P.3.c.030 Low dose versus standard dose of antipsychotics for relapse prevention in schizophrenia: a meta-analysis by H. Takeuchi; D.C. Mamo; T. Suzuki; T. Arenovich; H. Uchida (S527-S528).

P.3.c.032 Gender differences and risk of metabolic abnormalities in patients under long-term antipsychotic treatment by G. Cerveri; A. Mazzocchi; L.S. Volonteri; I. Netti; C. Mencacci (S528-S529).

P.3.c.031 Low daytime activity and increased night rest time during antipsychotic treatment of schizophrenia by A. Wichniak; E. Waliniowska; I. Musinska; K. Czasak; A. Wierzbicka; W. Jernajczyk; M. Jarema (S528).

P.3.c.023 Delirium psychoses caused by antiparkinsonian drugs by J. Santiago Sastre; A. Sánchez Peña (S523-S524).

P.3.c.065 Aripiprazole in the treatment of kleptomania: a case study by S. Mercan; O.G.U.Z. Karamustafalioglu; V. Karabulut; H. Sengul (S547-S548).

P.3.c.066 Treatment of cervical tardive dystonia with botulinum toxin type-A: two case reports by E. Marini; P. Georgila; N. Kouroumalos; V. Nikolopoulos; N. Tagaris; D. Sakkas (S548).

P.3.e.008 A programme for the emotional intelligence development of chronic mental patients by M.A. Sánchez Peña; J. De Santiago Sastre (S571-S572).

P.3.e.013 Psychiatric and non-psychiatric comorbidity in patients with psychotic disorders by M. Garcia Mahia; M. Vidal Millares; C. Armas Barbazan; L. Pérez Ramírez; J. Bajo Lema (S574-S575).

P.3.e.012 Validity of the Functional Remission On General Schizophrenia (FROGS) scale: second validation study by C. Lançon; F. Rouillon; P.M. Llorca; P. Gorwood; F.J. Baylé (S574).

P.3.e.00l Initial motivation predicts long-term adherence to pharmacological treatment by I. García-Cabeza; M.S. Olmeda; M. Salgado (S567-S568).

P.3.e.003 The relative association between four treatment-emergent adverse events and health-related quality of life by I. Ruiz; C. Adrianzen; C. Arango-Dávila; D. Martinez-Araujo; R. Walton; J. Maria-Haro; D. Novick; M. Dossenbach; J. Karagianis (S568-S569).

P.3.e.014 Membrane fatty acid levels as a predictor of treatment response in schizophrenia by T. Sumiyoshi; M. Matsui; Y. Higuchi; T. Itoh; H. Itoh; H. Arai; C. Takamiya; Y. Kawasaki; M. Suzuki; M. Kurachi (S575).

P3.e.024 Social cognition: response to treatment in first episode psychosis by R. Schoeman; P.P. Oosthuizen; R. Emsley (S580-S581).

P3.e.023 Statistical approaches in a global era: integrating multi-regional studies by B. Parsons; C. Siu; N. Schooler; S. Potkin; G. Cohen (S580).

P.3.f.001 Compliance over 8 year of follow-up in first psychotic episodes by S. Barbeito; P. Vega; A. Ugarte; B. Fernandez de Corres; P. López; A. González-Pinto (S581).

P.3.f.004 Regulation of the GABA cell phenotype in neurodevelopmental model of schizophrenia in rats by A. Basta-Kaim; B. Budziszewska; M. Leskiewicz; M. Kubera; K. Fijal; W. Lason (S583).

P.3.e.022 Schizophrenia and pregnancy: long-term study of a women-on-treatment sample in the community by M.L. Zamarro; D. Crespo; A. Cordero; R. Gutierrez; J. Ramos (S579-S580).

P.3.e.017 Brain activation preceding auditory verbal hallucinations by I. Sommer; K.M. Diederen; R.S. Kahn (S576-S577).

P.3.e.020 Early medication adherence and insight change in first episode psychosis by M. Lepage; M. Bodnar; L. Buchy; R. Joober; A.K. Malla (S578-S579).

P.3.d.02l Long-term treatments with low and high-dose olanzapine changed hepatocyte numbers in rats by E. Odaci; H. Bilen; A. Hacimuftuoglu; O.N. Keles; I. Can; M. Bilici (S566).

P.3.d.002 Hyperglycemia and antipsychotic treatment in patients on methadone maintenance by L. Barbadillo; E. Zapirain; A. Lopez; E. Usoz; A.V. Gil; A. Calvo (S554-S555).

P.3.d.003 Metabolic syndrome and antipsychotic treatment in patients on methadone maintenance by E. Zapirain; L. Barbadillo; O. Eizaguirre; A.L. Odriozola; A. Álvarez; M.P. Aizpuru (S555-S556).

P.3.c.074 L-lysine as an add-on treatment in patients with schizophrenia by C. Wass; D. Klamer; E. Katsarogiannis; K. Fejgin; E. Palsson; J. Svensson; I. Bogren; J.A. Engel; M. Berglund; B. Rembeck (S553).

P.3.c.067 The effects of amisulpride on weight and metabolic parameters in psychotic patients with surcharge weight by J. Monreal Ortiz; D. Chesa Vela; E. Surribas Leza; C. Franquelo Cruz (S548-S549).

P.3.c.072 Clinical differences between classical and atypical long acting antipsychotics in a community setting by J.M. Pelayo-Teran; O. Fernández-Torre; P. Trabajo-Vega; J. Martínez-Diez; C. Ordóñez-Prieto; R. Casado-Martínez; N. Varela-Aller; M. Álvarez-Bermejo; V. Quintana-González; C. Villaverde-Amieva (S552).

P.3.c.071 Catechol-o-methyltransferase val158met in first episode psychosis: prognostic factor or negative trait marker? by J.M. Pelayo-Teran; R. Pérez-Iglesias; I. Mata; J. Vázquez-Bourgon; E. Carrasco-Marín; X.L. Vázquez-Barquero; B. Crespo-Facorro (S551).

P.3.d.006 Effects of postnatal intermittent hypoxia on prepulse inhibition and locomotor activity in rats by R. Barbosa da Silva; K. Yamada; S. Satake; J.C. Perry; V. D'Almeida (S557).

P.3.d.016 Effect of olanzapine on MK-801-induced impairment of memory in the radial-arm maze test in mice by I. Komsuoglu; O. Mutlu; G. Ulak; F. Yildiz Akar; F. Erden (S563).

P.3.d.015 Enhanced cortical dopaminergic and glutamatergic transmission and antipsychotic-like effect of risperidone by idazoxan by M.M. Marcus; C. Wiker; O. Frånberg; A. Konradsson-Geuken; X. Langlois; K. Jardemark; T.H. Svensson (S562-S563).

P.3.d.017 Behavioural and molecular effects of N-desmethylclozapine and clozapine in an animal model of schizophrenia by A. Ertugrul; E. Saka; H. Ozdemir; A. Vural; Y. Ozdemir; H.Y. Meltzer; T. Dalkara (S563-S564).

P.3.d.014 Modification of cortical inhibition by paliperidone or risperidone: preliminary results by L. Ustohal; R. Prikryl; H. Kucerova; L. Havlaskova; E. Ceskova (S561-S562).

P.3.d.009 Effects of olanzapine and sertindole on MK-801 induced visual memory deficit in mice by O. Mutlu; I. Komsuoglu; G. Ulak; F. Erden; F. Yildiz Akar (S559).

P.3.d.008 Translating antipsychotic efficacy across species based on free (unbound) drug concentrations by C. Bundgaard; C.K. Olsen; C. Sveigaard; B. Steiniger-Brach (S558).

P.3.d.010 Pharmachological treatment in first psycotic episodes: glutamate and BDNF levels by S. Ruiz De Azua Garcia; S. Barbeito; S. Alberich; J.R. Pecina; M. Hernanz; A. González-pinto (S559-S560).

P.3.d.012 The effects of single dose aripiprazole and haloperidol on resting blood flow in healthy volunteers by R. Handley; F. Zelaya; A.A.T.S. Reinders; T. Marques; S. Kapur; R. Murray; P. McGuire; S. Williams; C. Paríante; P. Dazzan (S560-S561).

P.2.e.027 Do mood stabilizers protect patients with bipolar disorders from negative effects of life events? by S. Ben Nasr; Y. El Kissy; G.H. Amara; R. Hamdi; B. Ben Hadj Ali (S463-S464).

P.2.e.026 Valproate for acute bipolar depression: systematic review and meta-analysis by A.H. Young; J.M. Azorin; G. Perugi; E. Vieta; C. Bowden; V. Cornelius; L.A. Smith (S463).

P.2.e.028 Prevalence and correlates of obesity and overweight during treatment in patients with bipolar I disorder by A. Mechri; A. Ezzaher; D. Haj Mouhamed; W. DouM; M.E. Najjar; L. Gaha (S464-S465).

P.2.e.029 Levetiracetam in the management of bipolar depression: a randomized, double-blind, placebo controlled trial by A. Saricicek; K. Maloney; B. Lorberg; A. Muralidharan; B. Ruf; H. Blumberg; J. Hu; B. Pittman; G. Sanacora; Z. Bhagwagar (S465).

P.2.e.031 Metabolic syndrome in bipolar disorders in Spain: findings from the population-based case-control BIMET-VIVA study by R. Gabriel-Sánchez; L. Lorenzo-Carrascosa; M. Alonso-Arroyo; A. González-Pinto; E. Vieta; J.M. Montes; J. Rejas; F. Mesa (S466).

P.2.e.025 Ziprasidone with adjunctive mood stabilizer in maintenance treatment of bipolar disorder: metabolic profiles by O. Karayal; K. Ice; P. Chappell; J. Schwartz; C. Siu; E. Pappadopulos (S462-S463).

P.2.e.024 The effect of mania on cytokine status in bipolar illness by A. Remlinger; P. Wojciak; J. Karczewski; A. Kostrzewa; K. Wiktorowicz; J.K. Rybakowski (S462).

P.2.e.019 Predictors of recurrence in bipolar I disorder: a 2-year prospective study in a Tunisian sample by A. Mrad; L. Bouzgarrou; A. Mechri; W. Douki; M.F. Najjar; L. Gaha (S459).

P.2.e.018 Thyroid function index and recurrence in patients with bipolar disorders by J.M. Kang; D.H. Han; S.Y. Joo; J.W. Kim (S458-S459).

P.2.e.021 Time with symptoms in a cohort of bipolar outpatients followed prospectively during 18 months by C. De Dios Perrino; E. Ezquiaga Terrazas; A. García López (S460).

P.2.e.022 Effectiveness and safety of amisulpride's high dose in acute mania: an open label study by S. Arques; M.A. Pino; D. Villavicencio; P. Sierra; L. Livianos (S461).

P.2.e.032 Patterns in European and rest of world use of doctorate level raters in bipolar and schizophrenia clinical trials by D. Daniel; J. Bartko; N. Sartorius; E. Vieta; A. Butler; G. Moya (S466-S467).

P.2.g.003 Backpain in patients with depressive disorder by J. Martinovic; A. Miljatovic; A. Brankovic (S473).

P.2.g.005 A long term prospective study of mixed bipolar patients by A. González-Pinto; M.A. Jimeno; M. Gutiérrez; K. Haidar; M. Sainz (S474).

P.2.g.007 Interactions between cholesterol and serotonin transporter polymorphism on late-life depression by K.Y. Bae; J.A. Yoo; J.M. Kim; I.S. Shin; S.W. Kim; S.J. Yang; J.H. Ryu; T. Youn; I.S. Yoon (S475).

P.2.g.006 Effects of phosphatidylserine on depression in the elderly by T. Komori; T. Matsumoto; E. Motomura; T. Shiroyama (S474-S475).

P.2.g.001 Correlation between smoking and depression by I. Gabos Grecu; M. Gabos Grecu; T. Moica; A. Vesa; R. Crisan; M. Florea; G. Buicu; C. Gabos Grecu (S471-S472).

P.2.f.001 Mania-like behavioural abnormalities of diacylglycerol kinase β knockout mice by K. Kakefuda; A. Oyagi; K. Tsuruma; M. Shimazawa; K. Yokota; Y. Shirai; K. Horie; N. Saito; J. Takeda; H. Hara (S471).

P.2.e.035 Is bipolar affective disorder under-diagnosed in secondary care in the UK? by M. Agius; B. Iankov; L. Murphy; R. Zaman (S468-S469).

P.2.e.036 Determination of a Young Mania Rating Scale severity threshold and of the minimally clinical significant difference in the EMBLEM cohort by M. Lukasiewicz; S. Gerard; A. Besnard; B. Falissard; E. Perrin; H. Sapin; M. Tohen; C. Reed; J.M. Azorin (S469).

P.2.e.039 Prevalence and correlates of non-adherence with mood stabilisers in patients with bipolar I disorder by A. Mechri; L. Bouzgarrou; A. Mrad; W. DouM; M.F. Najjar; L. Gaha (S470-S471).

P.2.e.038 Mood disorders and obesity: quality of life and social functioning by E. Pierantozzi; L. Bossini; M. Roggi; L. Padula; R.N. Forgione; P. Castrogiovanni; A. Fagiolini (S470).

P.2.e.017 Aripiprazole combination with divalproex in patients with acute manic and mixed episode by W. Bahk; Y.S. Woo; M.Y. Chung; D.H. Kim; B.H. Yoon; J.H. Lee; Y.M. Ahn; S.K. Chung"; J.G. Kim; K.H. Lee (S458).

P.2.e.016 Sensitivity of a comprehensive rating scale for bipolar disorders to assess improvements with treatment by C. Bowden; J. Mintz; J. Gonzalez; V. Singh; P. Thompson; C. Bernardo (S457-S458).

P.2.d.029 The influence of mianserin on cytokines plasma levels in rats under chronic mild stress by K. Manikowska; P. Mikolajczak; M. Wojtys; T. Bobkiewicz-Kozlowska (S445-S446).

P.2.d.028 Influence of antidepressants on cytokines in lipopolysaccharide-stimulated primary rat mixed glial cell cultures by A.M. Bielecka; A. Pudelko; M. Paul-Samojedny; J. Kowalski; E. Obuchowicz (S445).

P.2.d.030 Glucocorticoid induced reduction in neural stem cell proliferation is counteracted by antidepressants by C. Anacker; P. Zunszain; L. Carvalho; S. Thuret; J. Price; C.M. Paríante (S446).

P.2.d.03l Trazodone increases extracellular serotonin levels in the frontal cortex of rats by B. Garrone; S. De Santi; D. D'Amico; A. di Matteo; L. Olivieri; M. Magnani; A. Comandini; A. Guglielmotti (S447).

P.2.d.033 Effect of desipramine and imipramine chronic administration on lipopolysaccharide-induced interleukin-1β levels in rat brain and plasma by E. Obuchowicz; A. Prymus; A. Bielecka; L. Drzyzga; M. Kot; W.A. Daniel; I. Krupka-Matuszczyk (S448).

P.2.d.032 Glycogen synthase kinase 3 (GSK-3β) an emerging target for neurological disease: in silico study to investigate the binding mode of trazodone by R. Ombrato; M.A. Alisi; N. Cazzolla; G. Corso; C. Manelfi; G. Mangano; M. Magnani; C. Milanese; L. Olivieri; L. Polenzani (S447-S448).

P.2.d.027 Psychopharmacological therapy of depressed patients requiring in-patient care by E. David; M. Bálint; E. Frey; R. Papp; G. Gazdag (S444-S445).

P.2.d.021 Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C properties by M. Mallei; S. Zappettini; L. Musazzi; E. Mocaer; C. Gabriel; M. Milanese; G. Bonanno; M. Popoli (S441-S442).

P.2.d.022 CYP2D6 P34S polymorphisms and mirtazapine responses in Koreans with major depression by M.S. Lee; H.Y. Lee; H.S. Chang; J.H. Paik; B.J. Ham; R.H. Kang; S.O. Jeon; Y.J. Jeong; H.M. Kim (S442).

P.2.d.023 Synergic mechanisms in the modulation of BDNF and Arc following agomelatine administration by F. Calabrese; R. Molteni; S. Pisoni; C. Gabriel; E. Mocaer; G. Racagni; M.A. Riva (S442-S443).

P.2.d.025 Paroxetine treatment in women with menopausal depression by V.F. Filovska; M.J.K. Jakovcevska; O.D. Dimova; I.N. Nedzipi (S443-S444).

P.2.d.024 Modulation of the neurotrophin BDNF in serotonin transporter mutant rats by F. Calabrese; R. Molteni; A. Cattaneo; F. Macchi; G. Racagni; M. Gennarelli; B.A. Ellenbroek; M.A. Riva (S443).

P.2.e.00l Predominant polarity as an outcome predictor in a clinical trial for bipolar depression by I.P. Pacchiarotti; A.R. Rosa; L.M. Mazzarini; F. Colom; M. Tohen; E. Vieta (S448-S449).

P.2.e.010 Nutritional, metabolic and endocrine disorders in patients with bipolar disorder: a systematic review by S. Jerónimo; J. Bobes; F. Rico-Villademoros; J.M. Montes; J. Mostaza; E. Vieta (S454).

P.2.e.013 Seasonal variations in bipolar disorder admissions in Galiza by I. Veiga Ramos; P. De Usabel; M.J. Mota; A. Arauxo (S455-S456).

P.2.e.009 Gynaecological and obstetric comorbidities in patients with bipolar disorder: a systematic review by J. Bobes; J.M. Montes; J. Mostaza; F. Rico-Villademoros; E. Vieta; J. Saiz-Ruiz (S453-S454).

P.2.e.008 Cardiovascular and respiratory comorbidities in patients with bipolar disorder: a systematic review by J.M. Montes; J. Saiz-Ruiz; E. Vieta; J. Mostaza; F. Rico-Villademoros; J. Bobes (S452-S453).

P.2.e.004 Age at onset in bipolar disorder by I.H. Paik; W. Ham; Y.S. Woo; M.H. Park (S450-S451).

P.2.e.005 Factors affecting recovery from mania in bipolar disorder in patients treated with atypical antipsychotics by T. Treuer; F.D. Yang; D. Dikeos; G. Tapia; M. Blinc Pesek; C. Hudita; T. Okasha; M. Molnar; Y. D'Yachkova; G. Harrison (S451).

P.3.a.033 Family association study in schizophrenia by P. Kapelski; P. Czerski; A. SzczepanMewicz; M. Skibinska; J. Rybakowski; J. Hauser (S499).

P.3.a.035 The Polish version of the InterSePT scale for suicidal thinking – reliability and validity by A. Mlodozeniec; M. Jarema; T. Szafranski; A. Leszczynska; K. Krysiak; K. Katarasinska-Pierzgalska (S500).

P.3.a.036 Drug-induced akathisia and suicidal ideation in schizophrenia inpatients by A. Mlodozeniec; M. Jarema; T. Szafranski; A. Leszczynska; K. Krysiak; A. Zebrowska (S501).

P.3.a.038 Computerized analyses of prosody in schizophrenia by S. Portuguese; S. Piantadosi; E. Gibson; B.M. Cohen; D. Ongur (S502).

P.3.a.037 Auto-antibodies in affective and schizophrenic disorders by I. Ganhao; E. Goncalves; P. Pedro (S501-S502).

P.3.a.032 The relationship between striatal dopamine function and frontal cortical function in the aetiology of psychosis by O. Howes; P. Fusar-Poli; P. Allen; R. Murray; P. Grasby; P. McGuire (S498-S499).

P.3.a.03l Comorbid depression and treatment attitude among out-patients with schizophrenia or schizoaffective disorder by A. Frikha; S. Brahem; A. Mhalla; S. Mlika; S. Ben Nasr; B. Ben Hadj Ali (S498).

P.3.a.027 Evaluation of clinical efficacy of social skills training in patients on continuous pharmacotherapy by E. Shimada; S. Niwa; N. Anzai; E. Ikebuchi; M. Nishizono (S495-S496).

P.3.a.028 Memantine precipitates psychosis in Kraepelinian's paraphrenia: case report and implications by B. Trancas; C. Vieira; A. Luengo; B. Pereira; J. Ribeiro; J. Ramos; A. Neto; M. Martins; G. Cardoso (S496).

P.3.a.030 A 6-month, double-blind trial of ziprasidone plus a mood stabilizer in subjects with bipolar I disorder by E. Vieta; C. Bowden; K.S. Ice; J.H. Schwartz; P. Wang; M. Versavel; O. Karayal (S497-S498).

P.3.a.029 The importance of working through the trauma of psychosis – the role of group therapy by B. Avgustin; N. Perovsek Solinc; M. Blinc Pesek; H. Korosec Javornik (S496-S497).

P.3.b.001 Predictors of social functioning in schizophrenia by A. Erol; E. Unal; E. Tune Aydin; L. Mete (S503).

P.3.b.010 Structural brain abnormalities and altered sensitivity to psychotomimetic drugs in neuregulin-1 knockout mice by C. O'Tuathaigh; G. O'Sullivan; C. O'Leary; O. Tighe; L. Desbonnet; D. Lai; R.P. Harvey; D.T. Croke; J.L. Waddington (S508-S509).

P.3.b.009 An fMRI study about verbal 'theory of mind' task in Korean schizophrenic patients by J. Son; S.I. Lee; C.J. Shin; S.K. Kim; I.K. Oh; H. Ghim; S.B. Lee; Y.R. Choi; Y.R. Kim; J.C. Yoo (S508).

P.3.b.01l Dysfunction of configural face processing in individuals at ultra-high risk for schizophrenia by H.S. Kim; N.Y. Shin; J.S. Choi; M.H. Jung; J.H. Jang; D.H. Kang; J.S. Kwon (S509).

P.3.b.012 Electrophysiological measures in schizophrenia and bipolar disorder by N. Domján; G. Csifcsåk; I. Szendi; Z. Janka (S509-S510).

P.3.c.001 Quality of life: sexual dysfunction in young people with schizophrenia treated with ziprasidone by C. Istikoglou; D. Vlissides; K. Michelidakis; O. Mikirditsian (S511).

P.3.b.013 Associations of 5HT2A receptor gene polymorphisms with symptoms of disorganisation in schizophrenia by L. Olajossy-Hilkesberger; B. Godlewska; M. Olajossy; H. Marmurowska-Michalowska (S510).

P.3.b.008 Dysbindin gene (DTNBP1) and schizophrenia in Korean population by J.J. Kim; C.U. Pae; T.Y. Jun; K.I. Jung; C.U. Lee; C. Lee; I.H. Paik (S507).

P.3.b.007 Homocystein and metabolic syndrome in schizophrenia by D. Cozman; M. Dronca; E. Craciun; M. Manea; B. Nemes (S506-S507).

P.3.b.003 The associations with apathy and neuropsychological deficits in schizophrenia by S. Kim; K.W. Yun; W.J. Lim; J.W. Choi; H.S. Park (S504-S505).

P.3.b.004 Abnormal behaviours of conditional heparin-binding epidermal growth factor-like growth factor knockout mice by H. Hara; A. Oyagi; Y. Oida; K. Kakefuda; M. Shimazawa; N. Shioda; K. Kitaichi; Y. Furuta; K. Fukunaga; S. Higashiyama (S505).

P.3.b.006 Hyperhomocysteinemia and individuality of psychotic disorders in childhood and adolescents by L. Kevere; S. Purvina; D. Bauze; M. Zeibarts; A. Rizevs; M. Caune; I. Purvins; R. Andrezina (S506).

P.3.a.003 The revolving door patients – are they different? by V. Novak Grubic; B. Zalar; M. Saje (S481-S482).

P.3.a.002 Brief psychotic disorder induced by pramipexole: a five-case study by M. Marinescu; Y. Bescond; C. Bescond; S. Voillet; S. Bulteau; M. Lejoyeux (S481).

P.3.a.006 Psychological treatment in the first psychotic episode by P. Vega Perez; S. Ruiz De Azúa; M. Martinez; S. Ron; R. Gonzalez Oliveros; J. Asua; A. Gonzalez-Pinto (S483-S484).

P.3.a.001 Sequential IM/oral ziprasidone and haloperidol in agitated patients with Schizophrenia: A naturalistic comparison by C. Fernando; V. Pérez-Solá; M. Gutierrez-Fraile; J.R. Gutiérrez-Casares; F. Mesa (S480-S481).

P.2.h.004 Development of a new affective temperament scale associated with the s alíele of 5-HTTLPR by X. Gonda; K.N. Fountoulakis; A. Laszik; Z. Rihmer; H.S. Akiskal; G. Bagdy (S480).

P.2.g.011 Painful physical symptoms in major depressive Turkish outpatients by O. Karamustafalioglu; C. Korulsan Ogutcen; M. Akbiyik; N. Kahraman; G. Alpak (S477).

P.2.g.010 Dissociative symptoms in patients with mood and anxiety disorders and potential correlation to antidepressant response by M.M. Moscariello; F. Ratti; A. Quartini; F.E. Forcen; J.N. Munuera; G. Bersani (S476-S477).

P.3.a.008 Effects of cognitive remediation in schizophrenia patients by M. Rodriguez; R. Kawaciukova; L. Bankovska-Motlova; P. Mohr; E.V.A. Dragomirecka; T. Novak; M. Preiss; J. Sediva (S484-S485).

P.3.a.009 Schizophrenia Related NRG1 single nucleotide polymorphisms Lead to Smooth Eye Pursuit Dysfunction in a population of young men by N. Smyrnis; E. Kattoulas; N.C. Stefanis; D. Avramopoulos; G. Papadimitriou; I. Evdokimidis; C.N. Stefanis (S485).

P.3.a.017 Paliperidone extended-release for the treatment of bipolar mania by C. Leotsakou; A. Sardis; C. Labiris; F. Kapsali; K. Papadopoulos; P. Pelka; A. Kalogeropoulou; M. Giovanoglou; E. Datsi; P. Paterakis (S489-S490).

P.3.a.020 Gender differences in hospitalised schizophrenic patients by M. Serrano Vazquez; M.M. Serrano Carton; M.C. Serrano Carton (S491-S492).

P.3.a.022 Executive function in deficit schizophrenia by P. Polgar; I. Bitter; S. Keri; P. Czobor (S492-S493).

P.3.a.02l Cannabis use and clinical presentation among a sample of first episode of schizophrenia patients by T. Moreno-Calle; R. Pérez-Iglesias; I. Mata; J. Mayoral-vanSon; J.M. Pelayo-Teran; O. Martinez-Garcia; G. Pardo; J.L. Vázquez-Barquero; B. Crespo-Facorro (S492).

P.3.a.015 Switching to aripiprazole from atypical antipsychotics in patients with schizophrenia by S.W. Kim; J.H. Lee; Y.H. Lee; K.H. Chung; J.H. Ryu; J.S. Yoon; J.M. Kim; J.A. Yoo; T. Youn; K.Y. Bae (S488-S489).

P.3.a.01l The effect of stress and antipsychotic treatment on inflammatory and metabolic markers in first-episode psychosis by V. Mondelli; M. Aas; M. di Forti; H. Fisher; R. Handley; T. Reis Marques; H. Taylor; P. Dazzan; R.M. Murray; C.M. Paríante (S486).

P.3.a.010 Clinical outcome in first episode of schizophrenia by R. Macrea; I. Miclutia; C.A. Popescu (S485-S486).

P.3.a.013 Insight and clinical outcome in first episode psychosis: 1-year follow-up study by C. Morelli; R. Ayesa-Arrióla; J.M. Pelayo-Teran; J.M. Rodriguez-Sanchez; R. Perez-Iglesias; I. Mata; B. Crespo-Facorro (S487-S488).

P.3.a.014 Psychotic disorder with underlying Graves disease: a case report by A.M. Zaharie; N. Racataianu; I. Miclutia; C. Ghervan (S488).

P.3.f.005 Corpus callosum abnormalities in schizophrenia: potential association to antipsychotic treatment by A. Quartini; A. Iannitelli; M. Paolemili; C. Di Biasi; G. Gualdi; G. Bersani (S583-S584).

P.3.f.006 NW-3509: a novel potent sodium channel blocker with antipsychotic potential by E. Iizzo; L. Faravelli; A. Ieraci; C. Sabido-David; C. Caccia; P. Melloni; K. Wedzony; M. Bortolato; R. Frau; P. Salvati (S584).

P.7.a.005 Repeated transcranial magnetic stimulation in Tourette's syndrome by M.H. Lim; H.W. Kim; K.K. Lee; K.C. Paik; S.B. Lee; J.H. Chae (S680-S681).

P.7.a.007 Is there a link between a history of childhood trauma and cognitive impairment in first-episode psychosis? by M. Aas; V. Mondelli; A. Reichenberg; M. Di Forti; B. Wiffen; R. Handley; H. Taylor; R. Murray; P. Dazzan; C.M. Pariante (S682).

P.7.a.008 Safety and efficacy of ziprasidone in pediatric bipolar disorder by R. Findling; M. DelBello; P. Wang; B. Gundapaneni; M. Versavel; O. Karayal (S682-S683).

P.7.a.009 Negative life events and conduct disorder among adolescents by G.H. Amara; A. Frikha; S. Ben Nasr; B. Ben Hadj Ali (S683).

P.6.f.003 Rimonabant repeated treatment inhibits behavioral sensitization previously developed to morphine in mice by E.A.V. Marinho; R. Santos; A.J. Oliveira-Lima; F.W. Silva; M.A. Baldaia; R. Wuo-Silva; A.W. Hollais; P.B. Sousa; H.A. Fernandes; R. Frussa-Filho (S676-S677).

P.6.f.005 Effects of different basal levels of anxiety on locomotion of mice in a novel environment by J.L.S. Cunha; R. Levin; D.F. Fukushiro; C.L. Parti; V.C. Abílio; R. Frussa-Filho (S677-S678).

P.6.f.006 Genotype-dependent effects of stress on opiate reward and GABAA receptor subtypes in C57BI/6J and DBA/2J mice by W. Solecki; A. Wawrzczak-Bargiela; J. Kubik; W. Bilecki; R. Przewlocki (S678).

P.7.a.002 A long-term safety study of prolonged-release methylphenidate in adults with ADHD by B. Schaeuble; J. Singh; L.A. Adler; C. Orman; G.J. Pandina; J.M. Palumbo (S679).

P.7.a.001 Changes in the developmental trajectories of striatum in autism by M. Langen; H.G. Schnack; H. Nederveen; D. Bos; B.E. Lahuis; M.V. de Jonge; H. van Engeland; S. Durston (S678-S679).

P.7.c.004 Clinical effects and tolerability of aripiprazole in children and adolescents with psychiatric disorders by R. Ramos-Ríos; A.M. Gago-Ageitos; M. Vidal-Millares; J.A. Mazaira-Castro; M.D. Dominguez-Santos (S691).

P.7.c.003 Somnolence and sedation in adolescents with schizophrenia treated with aripiprazole (acute and long term follow-up) by J.Y. Loze; S.J. Mathew; R.D. McQuade; W.H. Carson; M. Nyilas; R.A. Forbes; T. Iwamoto; R. Mankoski; A. Pikalov (S690-S691).

P.7.d.001 Impact of psychiatric comorbidity on quality of life in adolescents with epileptic disorder by E. Beyoglu; Y. Taneli; O. Ozdemir; M.S. Okan; S. Taneli (S691-S692).

P.7.e.003 The relationship between parental age and child psychopathology by T. Fidan; I. Esin; H. Ceyhun; S. Gürsoy (S693-S694).

P.7.e.002 Pharmacogenetics of acute treatment of depression and anxiety in children and adolescents by S. Kronenberg; A. Apter; M. Carmel; A. Frisch; A. Weizman (S693).

P.7.C.002 Effects of aripiprazole on glucose, lipids and weight in adolescent patients: a pooled analysis of 2 clinical trials by J.Y. Loze; A. Pikalov; R. Baker; S. Kaplita; W.H. Carson; R. Owen; R.A. Forbes; M. Nyilas; T. Iwamoto; J.W. Newcomer (S689-S690).

P.7.b.005 Arginine vasopressin receptor gene-based single nucleotide polymorphism (SNP) analysis in ADHD by D. van West; J. Del-Favero; D. Deboutte; C. Van Broeckhoven; S. Claes (S686).

P.7.b.004 Neurobiological correlates of disruptive behaviour disorder in a normal population; differences between boys and girls by E. Platje; L.M.C. Jansen; R.R.J.M. Vermeiren; T.H.A.H. Doreleijers; P.A.C. van Lier; T. Frijns; J.M. Koot; W. Meeus (S685-S686).

P.7.b.006 Chronic methylphenidate or atomoxetine treatment alters BDNF expression in the brain of spontaneously hypertensive rats by A. Cattaneo; L. Caffino; A. Sesta; M. Ibba; E. Carboni; F. Fumagalli; M.A. Riva; M. Gennarelli (S686-S687).

P.7.b.007 Neurobiological factors as predictors for re-offending in adolescent males by M. De Vries-Bouw; A. Popma; L.M.C. Jansen; R. Vermeiren; T.H.A.H. Doreleijers (S687).

P.6.f.002 The effects of inhalation exposure to toluene on spatial and object recognition memory in rats by L. Chilachava; G. Maglakelidze; M. Zhvania; M. Dashniani; L. Gelazonia (S676).

P6.d.01l Comparison of behavioural consequences pre and postnatal morphine exposure in the rats offspring by Z. Gyarmati; J. Timár; M. Sobor; K. Király; Z. Furst (S663-S664).

P6.d.012 Effects of modafinil on cocaine-induced behavioral sensitization in mice by R. Wuo-Silva; H.A. Fernandes; R.P. Souza; L.H.F. Zanlorenci; L.T.C. Ribeiro; C.S. Oliveira; J.M.R. Maragno-Correa; L. Sanday; L.R. Bittencourt; R. Frussa-Filho (S664).

P6.d.013 The evaluation of the effect of food deprivation on the development of morphine dependence in rats by A. Nurten; A. Zengin; Z.G. Ozunal; E. Ozturk; N. Enginar (S664-S665).

P6.d.015 Effects of an environmental contra-conditioning strategy with aripiprazole in an animal model of cocaine dependence by A.J. Oliveira Lima; A.W. Hollais; E.A.V. Marinho; M.A. Baldaia; R. Wuo-Silva; R. Santos; H.A. Fernandes; C.A. Gerardi-Junior; L.A. Ferreira; R. Frussa-Filho (S666).

P6.d.014 MDMA self-administration is abolished in 5-HT2A receptor knockout mice by M.J. Orejarena; R. Maldonado; P. Robledo (S665).

P6.d.003 Opposite regulation of FADD and nuclear poly (ADP-ribose) polymerase (PARP) in brains of cocaine addicts by M. Alvaro-Bartolome; R. La Harpe; J.J. Meana; J.A. Garcia-Sevilla (S658-S659).

P6.d.004 Depressive-like behaviour and aripiprazole increase the drug intake in iv self-administration model in rats by J. Kucerova; J. Pistovcakova; D. Vrskova; M. Nemecek; A. Sulcova (S659-S660).

P6.d.005 Ultrastructural alteration of cortical serotonergic fibers after MDMA (ecstasy) treatment using a new TpH2 antibody by C. Ádori; P. Löw; R.D. Andó; L. Gutknecht; D. Papp; Z. Frank; J. Takács; G.G. Kovács; P. Lesch; G. Bagdyf (S660).

P6.d.007 Differential effects of acute and repeated amphetamine on two animal models of human novelty-seeking behaviour by D.F. Fukushiro; L.P. Saito; C.F. Lima; G.P. Oliveira; L. Cupersmid; M.D.G.B. Tacconi; R. Frussa-Filho (S661).

P6.d.006 Association between the cell adhesion molecule gene, personality traits and addictive behaviour in methamphetamine abuse by B. Lee; D. Kwon; Y. Kim; S. Cho; Y. Chung; J. Park; S. Kim; C. Kang; J. Kim; Y. Lee (S660-S661).

P6.d.016 Long-lasting effects of transient food deprivation on an animal model of addiction by E. de Almeida; R.P. Souza; R. Wuo-Silva; A. Takatsu-Colleman; V.P. Ricardo; L.H.F. Zanlorenci; T.F. Trombim; A.J. Oliveira-lima; E.A.V. Marinho; R. Frussa-Filho (S666-S667).

P.6.d.017 Profile of the N-substituted benztropine analog, AHN-1055, as a candidate treatment for cocaine addiction by A. Ferragud; C. Velázquez-Sánchez; A. Arcusa; V. Hernández-Rabaza; H.G. Gumus; A. Nácher; V. Merino; J. Murga; M. Cardá; J.J. Canales (S667).

P.6.e.006 The effects on the human body from the cessation of smoking by J.S. Seo; S.S. Lee; D.J. Kim; B.W. Nam; S.W. Moon; H.J. Go (S672).

P.6.e.007 Gender differences of nicotine dependence in South Korea by S.K. Kim; Y.R. Lee; M.J. Joe; H.J. Jeon; S.M. Chang; J.H. Lee (S673).

P.6.e.009 Substance use during pregnancy and child outcomes: a longitudinal study by M. Imaz; E. Gelabert; L.L. García-Esteve; P. Navarro; J. Sanjuan; R. Guillamat; A. Gutierrez; M. Torrens; K. Langorh; R. Martin-Santos (S674).

P.6.e.004 Hostility and impulsivity of nicotine dependence by S. Min; J. Whang; J. Shin; K. Park; H. Lee (S671).

P.6.e.003 Effect of sigarette smoking on treatment of schizophrenia with clozapine by N. Zivkovic; D. Pavicevic; G. Djokic; J. Lekovic (S670-S671).

P.6.d.018 Serotonin transporter and 5-HT2A receptor binding in human ecstasy and hallucinogen users by D. Erritzoe; V. Frokjaer; M. Christoffersen; W. Baare; T. Jernigan; T. Ramshoy; C. Svarer; G.M. Knudsen (S667-S668).

P6.d.020 Do dopaminergic drugs induce a place preference in normal rat? by Y. Zengin; N. Authier; P.M. Llorca; F. Durif (S668-S669).

P.8.a.002 The panel of selected genes involving in regulation of food intake in anorexia nervosa patients by M. Janas Kozik; M. Stachowicz; I. Krupka Matuszczyk; U. Mazurek; K. Krysta; I. Jelonek; A. Janas (S694-S695).

Keyword index (S743-S750).

Author index (S721-S742).

P.8.a.012 Psychiatric comorbidity in females with vaginismus by E.A. Yildirim; S. Cavas; M. Hacioglu; M. Yanik (S700-S701).

P.8.a.013 Psychotropic drug use evaluation after a therapeutic guide in a long term care centre by L. García-Sánchez; G. Porta-Rius; B. Pascual-Arce; M. Blanca-Tamayo; M.C. Pérez-Navarro; A. Sicras-Mainar; N. Muro-Perea (S701).

P.8.a.014 Serum lipid profiles and schizophrenia: ratio of LDL/HDL cholesterol as predict factor for acute phase schizophrenia by V. Slavkovic; S. Tosic Golubovic; G.D. Gugleta Dragoslava; Z.O. Zikic Olivera (S701-S702).

P.8.b.002 Disorders of neurotic and affective level in assessment of cardio-vascular risk in patients with aterial hypertension by N.P. Garganeyeva; A.I. Rozin; S.Y.U. Shtarik; D.S. Kaskayeva; V.N. Masunov; E.V. Ryabova (S702-S703).

P.8.b.001 Age-dependent plasticity changes of personality profile by J.S. Yi; H.S. Lee; Y.W. Jeon; S.H. Kim (S702).

P.8.a.009 The association between mental functioning and conversion disorder by D. Sakarya; V. Senturk; E. Arslan; A. Cevik (S698-S699).

P.8.a.004 Pharmacological treatment prescribed to emergency psychiatric patients over 65 years by J. Arcega; D. Corcoles; J.M. Gines; A. Malagon; A. Merino; A. Bulbena (S695-S696).

P.8.a.006 Consultation-liaison psychiatry service in obstetrics and gynecology, in Athens, Greece by I. Mourikis; A.V. Kouzoupis; M. Antoniou; A. Spyropoulou; A. Leonardou; M. Vogiatzi; I. Zervas; G.N. Papadimitriou (S697).

P.8.b.003 Affective symptoms, body mass index and metabolic syndrome: a life course approach by D. Gaysina; M. Richards; M. Hotopf; I. Colman; D. Kuh; R. Hardy (S703).

C.01.02 Treating insomnia by C. Espie (S705).

P.4.c.008 Benzodiazepines and salivary cortisol: the Netherlands study of depression and anxiety (NESDA) by L. Manthey; E.J. Giltay; T. Veen; S.A. Vreeburg; F.G. Zitman; B.W.J.H. Penninx (S608-S609).

P.4.c.007 Effect of escitalopram treatment on the relationship of pre- to postsynaptic serotonin-1A receptors in anxiety disorders by A. Hahn; R. Lanzenberger; M. Fink; P. Stein; L.K. Mien; M. Savli; E. Ammova; M. Mitterhauser; W. Wadsak; S. Kasper (S607-S608).

P.4.c.010 Effects of diazepam on the processing of aversive faces: a fMRI study by C.M. Del-Ben; C.A. Queiroz; T.A. Sanchez; W.C. Alves-Neto; V.G. Guapo; D.B. Araujo; F.G. Graeff (S609-S610).

P.4.d.002 The putative anxiolytic and antidepressant-like effect of Achillea millefolium L. extract in mice by I.P. Baretta; R.A. Felizardo; V.F. Bimbato; A. Gasparotto Júnior; C. Kassuya; R. Andreatini (S610-S611).

P.4.b.013 Cannabinoids receptors gene polymorphisms and anxiety traits by R. Martin-Santos; J. Undurraga; A.B. Fagundo; I. Royo; M. Gratacos; J.A. Crippa; M. Torrens; M. Farré (S603-S604).

P.4.b.012 Assessment of striatal dopamine release in obsessive-compulsive disorder using positron emission tomography by M. Figee; F. de Vries; N. Vulink; D. Cath; T. van der Doef; D. Veltman; T. van Balkom; A.A. Lammertsma; B.N.M. van Berckel; D.A.J.P. Denys (S603).

P.4.C.001 Drug prescriptions for treating insomnia in hospitalized patients by M.T. Amboage-Paz; J.A. Díaz-Peromingo; E. Fontela-Vivanco; S. González-Bardanca; M.J. Ávila-González; Y. Prieto-Paredes (S604).

P.4.c.004 Paroxetine in the treatment of panic disorder: a comparison between slow and standard up-titrations by M. Buoli; B. Dell'Osso; F.L. Lopes; S. Bortolussi; B. Benatti; A.C. Altamura (S606).

P.4.d.003 Increase in nociception and articular diameter after the dorsolateral periaqueductal gray chemical stimulation in rats by L.J. Bertoglio; C.R. Tonussi; E. Bressan; M.A. Martins; C.A.J. Stern (S611-S612).

P.4.d.004 Bilateral infusion of capsazepine in the rat hippocampus: effects on anxiety and spatial learning/memory by L.J. Bertoglio; F.H.M. Do Monte; A.S. Aguiar; C.J.P.A. Santos; R.S. Silva (S612).

P.4.e.010 The comorbidity of metabolic syndrome in patients with obsessive compulsive disorder by I. Erensoy Sacak; O. Karamustafalioglu; G. Alpak; R. Onem; O. Tankaya (S618).

P.4.e.009 Efficacy of trazodone in patients diagnosed with generalised anxiety disorder and benzodiazepine dependence by M. Zavoianu; A. Luchian; C. Tudor; G. Grigorescu; D. Vasile (S617-S618).

P.4.f.002 The absence of one-trial tolerance on a new animal model of anxiety by L.H.F. Zanlorenci; R. Wuo-Silva; R.P. Souza; T.F. Trombin; C.S. Oliveira; L.T.C. Ribeiro; D.F. Fukushiro; M.B. Calzavara; R. Frussa-Filho (S619).

P.5.a.002 Imaging of muscarinic acetylcholine receptors with 11C-3NMPB in vascular dementia and Alzheimer's disease by K. Nagata; D. Takano; T. Maeda; T. Nakase; T. Yamazaki; H. Saitoh (S620).

P.5.a.001 Dropouts due to other reasons than adverse events during clinical trials in Alzheimer's disease by C. Kani; A. Pehlivanidis; K. Papanikolaou; Z. Papadopoulou-Daifoti (S619-S620).

P.4.e.008 The factors that influence the therapeutic response to paroxetine in patients with panic disorder: longitudinal study by M. Ueda; T. Watanabe; Y. Saeki; A. Saito; K. Akiyama; Y. Inoue; S. Morita; G. Hirokane; N. Yamada; K. Shimoda (S617).

P.4.e.002 Changes in brain perfusion in the drug-naive panic patients with SPECT following cognitive-behavioural therapy by J. Kim; W. Nam; J. Chae; E. Chang; S. Ryu; K. Won; S. Zeon; Y. Chung (S613).

P.4.e.004 Agoraphobia treatment: antidepressant monotherapy and combined treatments by C.T. Pitti; M.L. Villaverde; W. Peñate; J.M. Bethencourt; J. de la Fuente; R. Gratia (S614-S615).

P.4.e.006 Does the inhalation of CO2 activate neurosteroids in healthy participants? A pilot study by J.E. Bailey; S. Phillips; A. Diaper; A. Rich; S. Lightman; D.J. Nutt (S615-S616).

P.4.a.009 Symptom improvement and functional recovery in patients with anxiety disorders by D.S. Baldwin; B. Bandelow; O.T. Dolberg; H.F. Andersen; D.J. Stein (S590-S591).

P.4.a.010 Burnout syndrome among physician of central, surgery and medical departments in a general hospital by M. Serrano Vazquez; M.C. Serrano Carton; M.M. Serrano Carton (S591).

P.4.a.007 Alprazolam/venlafaxine versus venlafaxine in the treatment of mixed depression and anxiety by M. Jakovcevska-Kujundziska; V. Lazarova; V. Filovska; N. Cadikovska (S589).

P.4.a.006 Internet-based screening of anxiety disorders by M. Van Ameringen; C. Mancini; W. Simpson; B. Patterson (S588-S589).

P.4.a.001 Clinical and sociodemographic features of patients with obsessive-compulsive disorder by E.A. Yildirim; M. Kasar; E. Ozcan; E. Albayrak; R.P. Gokalp; S. Ozer (S585-S586).

P.3.f.007 Microglia is widespread activated in recent onset schizophrenia: evidence from PET and post mortem studies by B. van Berckel; M. Yaqub; M. Bossong; R. Boellaard; A. Schuitemaker; A.A. Lammertsma; A.D. Windhorst; A. Rozemuller; W. Cahn; R.S. Kahn (S585).

P.4.a.005 Outcome predictors in patients with obsessive compulsive disorder: a prospective naturalistic study by B. Dell'Osso; M. Buoli; G. Colombini; S. Bortolussi; B. Benatti; M.C. Palazzo; A.C. Altamura (S588).

P.4.b.007 Aberrant default mode network in patients with obsessive-compulsive disorder: an fMRI study by J.H. Jang; J.H. Kim; W.H. Jung; D.H. Kang; J.M. Lee; C.H. Choi; J.S. Kwon (S600).

P.4.b.008 Are you afraid of the dentist? Validation of an MRI compatible paradigm using video stimulation in dental anxiety by U. Lueken; J. Kruschwitz; J. Hoyer; A.T. Gloster; H.U. Wittchen (S600-S601).

P.4.a.017 Psychological difference between noncoronary and coronary patients with chest pain by G. Nikolic; S. Tosic-Golubovic; L.J. Samardzic; D. Gugleta (S595).

P.4.a.018 Quadratic relation of frequent panic attacks with systolic blood pressure – the HUNT study by S.J.C. Davies; O. Bjerkeset; P.R. Jackson; D.J. Nutt; G. Lewis (S595-S596).

P.4.a.019 Carbon dioxide-induced respiratory symptoms and experimental panic in healthy volunteers by A. Colasanti; K. Schruers; R. van Diest; G. Esquivel; E. den Boer; A. Dandachi; E.J. Griez (S596).

P.5.a.003 Effects of BDNF val66met polymorphism on the association between physical activity and incident dementia by J.S. Yoon; K.Y. Bae; J.A. Yoo; J.M. Kim; S.W. Kim; S.J. Yang; T. Youn; Y.H. Lee; L.S. Shin (S621).

P.5.a.004 One-carbon metabolism and cognitive decline in an older Korean population by J.A. Yoo; K.Y. Bae; J.M. Kim; I.S. Shin; S.W. Kim; S.J. Yang; T. Youn; J.S. Yoon; J.H. Lee (S621-S622).

P.6.b.004 Apoptosis of immunocompetent cells in patients with alcoholism in dynamic of therapy by N. Bokhan; E.V. Zhernova; N.M. Vyalova; S.A. Ivanova (S645).

P.6.b.003 Effect of glutamine dipeptides on the levels of brain tissue amino acids and severity of the alcohol withdrawal in rats by P.S. Pronko; A.H. Shlyakhtun; T.I. Khomich; V.I. Satanovskaya; A.V. Gaishmanova (S644-S645).

P.6.b.005 Effect of N-methyl-D-aspartate glutamate receptor antagonist, memantine, on alcohol intake in C57BL/6 mice by S.G. Kim; H.K. Kim; H.C. Kim; Y.M. Jae; B.M. Choi; S.S. Lee; S.M. Shin (S645-S646).

P.6.b.007 Effects of acute alcohol consumption on alcohol attentional bias by S. Adams; A. Ataya; M.R. Munafò (S646-S647).

P.6.b.002 Matrix metalloproteinase 2 (MMP2) concentration among alcohol dependent inpatient women by B. Augustynska; A. Araszkiewicz; M. Dabkowska; A. Wozniak; E. Oglodek; G. Odrowaz-Sypniewska; W. Kosmowski; M. Kuligowska (S643-S644).

P.6.a.009 Zonisamide versus diazepam in the prevention of alcohol withdrawal syndrome by G. Rubio; G. Ponce; J.M. Arriazu; I. Martinez-Gras; F. Ferre (S640-S641).

P.6.a.008 A pilot study of the effectiveness of D-cycloserine during cue-exposure therapy in abstinent alcohol dependent subjects by B.J. Watson; B. Bowsher; S. Wilson; L.G. Taylor; N.J. Kalk; L. Griffin; A.R. Lingford-Hughes; M. Munafo; D.J. Nutt (S640).

P.6.a.010 Effects of zonisamide in the treatment of alcohol dependence by G. Rubio; F. Ferre; I. Martinez-Gras; G. Ponce; J.M. Pascual (S641).

P.6.a.01l Sexual dysfunction and alcohol abuse by T. Paparrigopoulos; T. Zabelis; E. Tzavellas; D. Karaiskos; R. Zaloni; X. Stachtea; G. Persefonis; J. Liappas (S641-S642).

P.6.a.013 Decision making, impulsivity and personality traits in alcohol dependent subjects by F. Struglia; A. Tomassini; P. Stratta; D. Spaziani; A. Rossi (S642-S643).

P.6.a.012 Public view of mental illness and alcohol abuse in Slovenia by B. Avgustin; R. Kobentar; B. Novak Sarotar; M. Radovanovic; M. Zorko (S642).

P.6.b.010 Rimonabant repeated treatment inhibits behavioural sensitisation previously developed to ethanol in mice by E.A.V. Marinho; M.A. Baldaia; A.J. Oliveira-Lima; R. Wuo-Silva; H.A. Fernandes; R. Santos; A.W. Hollais; C.A. Gerardi-Junior; L.A. Ferreira; R. Frussa-Filho (S648).

P6.c.008 Pharmacogenetic modulation of neurocognitive deficits in MDMA users: The role of catechol-O-methyltransferase, serotonin transporter SERT and 5HT2A polymorphisms by A.B. Fagundo; E. Cuyàs; A. Verdejo-Garcia; O. Khymenets; K. Langohr; J. Peña-Casanova; S. de Sola; R. Martín-Santos; M. Farré; R. de la Torre (S654).

P.6.c.007 Association between opioid receptor availability and anxiety in healthy controls but not in substance dependence by T.M. Williams; S.J.C. Davies; L.G. Taylor; D.J. Nutt; A. Lingford-Hughes (S653-S654).

P6.c.012 Efficacy of melatonin in methadone maintained patients with insomnia: results from an open comparison study by K.R. Stoychev; K.M. Ivanov; M.G. Alexandrova; R.D. Stoychev; L.Z. Tumbev; D.K. Kirov (S656-S657).

P6.C.0111 Effectiveness of the benztropine analogs in preventing the neurochemical and behavioural effects of psychostimulants by C. Velázquez-Sanchez; A. Ferragud; V. Hernandez-Rabaza; A. Arcusa; H.G. Gumus; A. Nácher; V. Merino; M. Cardá; J. Murga; J.J. Canales (S656).

P.6.c.006 Personality disorders in a dual diagnosis unit by D. Martínez-Sanvisens; G. Mateu-Codina; L. Díaz-Digón; L. Morro-Fernández; A. Martínez-Fernández; A. Muñoz-Champel; G. Vallecillo-Sánchez; M. Torrens-Mélich (S652-S653).

P.6.c.005 Benzodiazepines use withdrawal tapering gradually with pregabalin: findings from the medical practice by G. Rubio; J. Bobes; G. Cervera; A. Terán; M. Pérez; V. López-Gómez; J. Rejas (S652).

P.6.c.001 Is attention affected by cocaine use? A case-control study by E. Ochoa; A. Madoz-Gúrpide (S649-S650).

P.6.b.01l The catechol-O-methyltransferase va1158Met genotype in prefrontal dopamine sensitivity in alcohol dependent patients and healthy controls by A. Schellekens; S. Hoppenreijs; A. Oosterwijck; B. Franke; J. Buitelaar; C. Jong; A. Cools; R. Verkes; B. Ellenbroek (S649).

P.6.c.003 Negative affect in depressed versus non-depressed smokers after brief nicotine abstinence by N. Kilzieh; S. Rastam; W. Maziak; A. Tapp; T. Eissenberg (S651).

P.6.c.004 History of consumption of toxic substances in psychiatric inpatients by M. Vidal Millares; M.C. García Manía; C. Armas Barbazan; P. De Usabel Guzman (S651-S652).

P.5.c.00l Treatment of sex offenders with the long-acting GnRH analogue triptorelin – a case series by P.J. McNally; R. Brock; P. Chabra; R. Kaler; M. Das; M. Kamal (S628).

P.5.c.002 Pregabalin, venlafaxine extended release or their combination in chronic neuropathic pain treatment by V. Jamie; D. Ravanic; S. Djukic Dejanovic; D. Ignjatovic Ristic; Z. Bukumiric (S628-S629).

P.5.d.002 Level of oxidative stress in patients with multiple sclerosis in process of therapy by S.A. Ivanova; N.V. Krotenko; L.P. Smirnova; V.M. Alifirova (S629-S630).

P.5.a.005 Adjunctive use of amisulpride on acetylcholine inhibitors therapy for the treatment of psychotic symptoms in Alzheimer's disease by C. Theleritis; A. Politis; M. Passa; F. LentidaM; E. Stamouli; A. Maillis; G.N. Papadimitriou (S622).

P.5.a.007 Aβ AFFITOPES as active vaccines in the treatment of Alzheimer's disease: preliminary results of two phase I studies by A. Kutzelnigg; A. Schneeberger; M. Brunner; D. Meshkat; P. Dai-Bianco; A. Laggner; D. Winkler; S. Kasper; E. Auff; M. Schmitz; M. Müller (S623).

P.5.a.008 Effects of memantine on functional communication in moderate Alzheimer's disease: results of a 12-week placebo-controlled trial by S. Graham; J. Saxton; M. Woodward; N. Gilchrist; F. Potocnik; R.K. Hofbauer; S.Y. Yu; H. Hsu; J.L. Perhach (S624).

P.5.b.001 Expression of certain apoptotic regulators in a pharmacological experimental model of Alzheimer's disease by S. Hasanagic; Z. Kundurovic; A. Kucukalic; F. Gavrankapetanovic; N. Bilalovic; M. Petrisic-Salkovic; P. Riederer (S625).

P.5.d.003 Decreased striatal dopamine turnover following administration of 7-nitroindazole to rats with L-DOPA-induced dyskinesia by E.A. Del Bel; R.S. Szawka; F.E. Padovan-Neto; C.A. da-Silva; J.A. Anselmo-Franci (S630-S631).

P.5.d.004 Behavioural changes in wistar and spontaneously hypertensive rats in kainate model of epilepsy by J. Tchekalarova; D. Pechlivanova; P. Markova; A. Stoynev (S631).

P.6.a.003 Oxidative stress and role of salivary peroxidase in acute and chronic alcohol intoxication by N. Waszkiewicz; S.D. Szajda; B. Konarzewska; A. Szulc; M. Waszkiewicz; A. Kepka; A. Zalewska; M. Cechowska-Pasko; K. Zwierz (S637).

P.6.a.005 Factors influencing drinking behaviour during pregnancy in Korean women by S.G. Kim; H.C. Kim; S.S. Lee; S.M. Shin; H.K. Kim; Y.M. Jae; B.M. Choi (S638).

P.5.f.002 Involvement of tetrahydrobiopterin in delirium after cardiac surgery by D. Fekkes; R.J. Osse; J.H.M. Tulen; R.C. van der Mast; A.J.J.C. Bogers; M.W. Hengeveld (S635).

P.5.e.005 Charles Bonnet Syndrome: a conceptual revision and review of a case report by M. Serrano Vazquez; M.C. Serrano Carton; M.M. Serrano Carton (S633-S634).

P.2.d.018 Mechanisms contributing to the regulation of the different phases of neurogenesis by agomelatine by A. Soumier; S. Lortet; F. Masmejean; C. Gabriel; E. Mocaer; M. Millan; A. Daszuta (S439-S440).

P.1.b.013 Chronic sleep deprivation and pain perception by L. Sahin; M. Ascioglu; E. Taskin; A.S. Arris (S247-S248).

P.1.b.007 Developmental expression and activity of carboxylesterase 1 and carboxylesterase 2 in mouse and human by H.J. Zhu; D.I. Appel; J.L. Donovan; C.L. DeVane; J.S. Markowitz (S244-S245).

P.1.b.002 Night-time/daytime and daytime/daytime patterns of melatonin levels by A.L. Morera; P. Abreu-Gonzalez; A. Orozco-Sanmartin; M. Henry; A. Guerra-Reyes; A. Garcia-Hernandez; L. Fernandez-Lopez; C.R. Morales-García; E. Diaz-Mesa; J. Monzon-Diaz (S241-S242).

P.1.b.005 Significance of fatigue and insomnia complaints in the psychiatric emergency room by D. Neu; P. Minner; O. Le Bon; L. From; P. Linkowski; P. Verbanck (S243-S244).

P.1.c.008 D-serine adjuvant treatment alleviates motor and behavioural symptoms in idiopathic Parkinson's disease by U. Heresco-Levy; D.C. Javitt; Y. Gelfin; Y. Kaufman; R. Levin; I. Korn-Lubetzki; B. Bloch; H. Wolosker; I. Kremer (S255-S256).

P.1.c.012 Efficacy and safety of duloxetine 60-mg and 120-mg daily in patients hospitalised for severe depression by S. Brecht; D. Desaiah; E. Marechal; A. Santini; J. Podhorna; J.D. Guelfi (S258).

P.1.c.006 Targeted delivery of PEGylated liposomes to gap junction protein Connexin-43 (Cx43) positive C6 glioma cells by V.P. Baklaushev; O.I. Gurina; N.F. Grinenko; Y.U.A. Jhyrkov; V.P. Chekhonin (S254-S255).

P.1.c.002 Cannabidiol lowers body weight gains in rats by B. Ignatowska-Jankowska; M. Jankowski; W. Glac; A.H. Swiergiel (S252).

P.1.c.003 Opiates and SSRI's: risk for serotonin syndrome by L. Timmerman; A.V.D. Hoek-Mensink (S252-S253).

P.1.a.026 Impaired neurogenesis in schizophrenia: results from a multiarray study with schizophrenics and normal controls by P. Belmonte-de-Abreu; H.M. Brentani; M.I. Lobato; C.S. Gama; D. Carraro; J.A. Palha (S240).

P.1.a.025 Association study of rs6916861 polymorphism of the FYN gene in bipolar disorder and it subtypes by A. Leszczynska-Rodziewicz; A. Rajewska-Rager; A. Szczepankiewicz; M. Skibinska; M. Dmitrzak-Weglarz; J. Hauser (S239-S240).

P.1.a.004 Modulation of presynaptic and postsynaptic plasticity by chronic mild stress and decreased vesicular glutamate transporter VGLUT1 levels by N. Elizalde; P.M. Pastor; A.L. Garcia-Garcia; F. Serres; J. Huarte; J. Del Rio; T. Sharp; R.M. Tordera (S227).

P.1.a.007 The role of insulin receptor substrate-1 Gly972Arg polymorphism in the pathogenesis of Alzheimer's disease by A. Juhasz; A. Fehér; A. Rimanóczy; M. Gálfi; J. Kálmán; Z. Janka (S228-S229).

P.1.a.009 Impulsivity and the C(-1019)G functional polymorphism of the HTR1A gene by A. Benko; J. Lazary; E. Molnar; X. Gonda; D. Pap; G. Juhasz; G. Bagdjr (S230).

P.1.a.008 Menopausal status could modulate the association between 5-HTTLPR and antidepressant efficacy in depressed women by F. Gressier; C. Verstuyfl; E. Bouaziz; P. Hardy; L. Becquemont; E. Comible (S229).

E.05.01 Schizophrenia: when does pharmacogenetics overlap genetic vulnerability? by P. Gorwood; N. Hamdani; C. Dubertret; P. Ramoz (S222).

P.1.a.010 The contribution of genetic vulnerability to the multiformity of isotretinoin-induced psychiatric adverse events by V.P. Kontaxakis; P. Ferentinos; B. Havald-Kontaxató; G.N. Papadimitriou (S230-S231).

P.1.a.020 Oxytocin receptor polymorphisms and adult attachment style in patients with depression by M. Abelli; B. Costa; S. Pini; P. Gabelloni; L. Lari; A. Cardini; C. Gesi; A. Lucacchini; G.B. Cassano; C. Martini (S236-S237).

P.1.a.019 Serotonin transporter gene promoter polymorphism, education, depression and relations with partner by T. Kurrikoff; J. Maestu; N. Nordquist; L. Oreland; J. Harro (S236).

P.1.a.022 Cytosolic phospholipase A2 Banl and cyclooxygenase-2 G-765C polymorphisms in Alzheimer's disease by A. Feher; A. Juhász; A. Rimanóczy; J. Kálmán; Z. Janka (S238).

P.1.a.024 Association study of rs2289656, polymorphism of the NTRK2 gene with bipolar disorder and it subtypes by A. Rajewska-Rager; A. Leszczynska-Rodziewicz; A. Szczepankiewicz; M. Skibinska; M. Dmitrzak-Weglarz; J. Hauser (S239).

P.1.a.023 Association study between WNT2 polymorphisms and the susceptibility to schizophrenia in Korean population by D.K. Hwang; H.J. Kim; S.V. Yim; B.K. Choe; J.K. Park; J.W. Kim; S.J. Hong; J.H. Chung (S238-S239).

P.1.a.018 Admixture analysis in pharmacogenetics: serotonergic system genes and antipsychotic response by V. De Luca; F. Panariello; R. de Souza; D. Muller; H. Meltzer; S.G. Potkin; J. Lieberman; J.L. Kennedy (S235-S236).

P.1.a.017 Association study between IL-10 and TNF-a genes and tardive dyskinesia in Korean schizophrenia by S.G. Kang; I.E. Choi; H.Y. Lee; H.J. Lee; M.S. Lee; L. Kim (S235).

P.1.a.013 Association study of cannabinoid receptor gene with olanzapine-induced weight gain in schizophrenia by S.G. Kang; J.E. Choi; Y.M. Park; H.J. Lee; S.H. Lee; L. Kim (S232-S233).

P.1.a.014 Variations in the catechol-O-methyl-transferase gene are associated with impulsivity by G. Juhasz; J. Lazary; D. Downey; E. Pegg; D. Chase; K. Mekli; A. Payton; G. Bagdy; I.M. Anderson; J.F.W. Deakin (S233).

P.1.a.015 Relationship of MAO-A and catechol-O-methyltransferase gene polymorphisms to plasma monoamine metabolites levels in patients and controls by M. Zumarraga; N. Basterreche; A. Arrúe; M.I. Zamalloa; R. Dávila; M.A. González-Torres; J. Guimón (S233-S234).

P.1.c.014 The novel antidepressant, agomelatine, blocks cerebral 5-HT2C receptors in vivo: a phMRI challenge study in rats by I. Linnik; S. McKie; J.A. Stark; S. Luckman; L. Seguin; E. Mocaer; M.J. Millan; B. Deakin; S.R. Williams (S259).

P.l.c.055 Acute stressor improves memory retrieval of discriminative avoidance task in mice by A.L. Takatsu-Coleman; C.L. Patti; M.L. Andersen; S. Tufik; R. Frussa-Filho (S283).

P.l.c.054 Opioid receptors of dorsomedial and ventrolateral periaqueductal grey matter modulate the post-ictal antinociception by R.L. Freitas; L.I. Bolognesi; A. Twardowschy; F.M.A. Correa; N.R. Sibson; N.C. Coimbra (S282-S283).

P.l.c.056 The most frequent used drugs at psychiatric clinical centre Kragujevac in 2007 by G. Mihajlovic; S. Djukic Dejanovic; B. Radmanovic; M. Borovcanin (S283-S284).

P.l.c.057 Effects of trazodone on sleep, respiratory and nocturnal movement variables in insomniac somatoform pain patients by W. Prause; B. Saletu; P. Anderer; E. Grátzhofer; G.M. Saletu-Zyhlarz; M. Aigner (S284).

P.l.c.058 Evaluation of an inpatient therapeutic interchange protocol for second generation antidepressants and clinical follow-up by F. Martínez-Granados; E. Climent-Grana; E. Perez-Martinez; J.P. Ordovas-Baines (S284-S285).

P.l.c.052 Paclitaxel induced pain and its character by A. Hacimuftuoglu; F. Saruhan; H. Suleyman; Z. Halici; E. Cadirci; D. Cetin; B. Polat (S281).

P.1.c.046 Pharmacogenetics of antidepressant drug response – a case report by M. Grgic; D. Degmecic; N. Boina; A. Dujmovic (S278).

P.1.c.048 Brain histamine-3 receptors as a potential target of novel strategies in the treatment of mental disorders by J.H.A. Folgering; G. Flik; E. Dremencov; T.H.I.F. Cremers; B.H.C. Westerink (S279).

P.1.c.049 Relation of proepileptic activity of indomethacin with adrenal gland hormones by H. Suleyman; A. Hacimuftuoglu; E. Cadirci; A. Albayrak; B. Polat; H.H. Alp; Z. Halici (S279-S280).

P.1.c.060 Effect of agmatine on pentilentetrazole-induced kindling in rats by F. Aricioglu; Z. Agalar; M. Kaya; C. Gurses (S285-S286).

P.1.d.012 Role of the endocannabinoid system and vanilloid TRPV1 channels in the phenotype of dopamine D3 receptor knock-out mice by V. Micale; L. Cristino; A. Tamburella; S. Petrosino; G.M. Leggio; V. Di Marzo; F. Drago (S294).

P.1.d.01l Multilevel phenotyping of NOS-I knockdown mice by S. Kittel-Schneider; T. Wultsch; S. Chourbaji; E. Grunblatt; M. Gerlach; L. Gutknecht; A. Schmitt; P. Gass; K.P. Lesch; A. Reif (S293).

P.l.c.044 Paradoxical effects of GABA on the in vivo uptake of the partial inverse GABA agonist [3H]Ro15-4513 in rat brain by R.J. Tyacke; E.S.J. Robinson; A. Harris; A.R. Lingford-Hughes; D.J. Nutt (S276-S277).

P.1.c.024 Aripiprazole augmentation for treatment of patiens with major depression refractory to antidepressants by C. Leotsakou; A. Sardis; A. Kalogeropoulou; C. Labiris; F. Kapsali; K. Papadopoulos; P. Pelka; M. Giovanoglou; E. Mantzari; P. Paterakis (S265).

P.1.c.023 GABA-A receptor-mediated neurotransmission in ventromedial hypothalamus modulates fear and antinociception by R.L. Freitas; M.A. Castiblanco-Urbina; A. Uribe-Mariño; D.H. Elias-Filho; N.C. Coimbra (S264-S265).

P.1.c.026 Opioid and nonopioid stress-induced analgesia are mediated by spinal 5-HT7 receptors by A. Dogrul; M. Seyrek; M.S. Deveci; S. Kahraman (S266-S267).

P.1.c.027 Effects of modafinil on contextual spatial memory retrieval in sleep-deprived mice by C. Piérard; P. Liscia; C. Tronche; M. Coutan; B. Poly; D. Béracochéa (S267).

P.1.c.016 Neuropharmacological activity of new l-valine peptidomimetics – in vitro and in vivo studies by E. Encheva; L. Tancheva; M. Novoselski; V. Petkov; J. Chakalarova; G. Gorneva; D. Tsekova; I. Gurt; E. Katz (S260-S261).

P.1.c.017 Neuropsychiatric adverse drug reactions (ADRs) and neuropsychiatric drugs-induced ADRs in a tertiary care hospital by M. Ponte; P.F. Garcia Merletti; S. Cráneo; P. Staltari; M.L. Dupont; A. Wachs; A. Noel (S261).

P.1.c.018 Different neurochemical effects of R and S enantiomers of tetrahydroisoquinoline on dopamine metabolism in rat brain by L. Antkiewicz-Michaluk; I. Romanska; J. Boksa; A. Bojarski; J. Michaluk (S261-S262).

P.1.c.020 Histological outcome after oxcarbazepine treatment in the asphyxiated neonatal rat brain by G. Papazisis; D. Kapoukranidou; I. Kalpidis; M. Albani; D. Kouvelas (S263).

P.1.c.019 Vulnerability to major psychiatric disorders, response to treatment and medical comorbidity – shared genetic factors? by H.H. Stassen; I.G. Anghelescu; S. Braun; K. Hoffmann; D. Rujescu; C. Scharfetter; A. Szegedi; A. Tadic (S262).

P.1.c.039 The effects of valproic acid on the pancreas of rats by J.H. Chung; B.K. Choe; S.V. Yim; J.K. Park; S.J. Hong; J.W. Kim (S274).

P.l.c.038 Modulation of dopaminergic activity in the mesolimbic system by trace amine-associated receptor 1 (TAAR1) modification by E.G. Revel; A. Bradaia; G. Trube; H. Stalder; L. Ozmen; J.G. Wettstein; B. Bettler; M.C. Hoener (S273).

P.l.c.040 Neuroprotective effect of timing for vinpocetine treatment on cerebral ischemia/reperfused rats by C. Kayacilar; D. Tekin; A. Zengin; A. Nurten; I. Kara (S274-S275).

P.l.c.041 The role of pro-inflammatory cytokines IL-ip and IL-6 on proliferation of human hippocampal neural stem cells by P. Zunszain; C. Anacker; L. Carvalho; S. Thuret; J. Price; C.M. Paríante (S275).

P.l.c.043 ACR325: a dopaminergic stabiliser that displays state-dependent effects in-vivo by H. Pontón; T. Dyhring; M. Edling; F. Pettersson; C. Sonesson; B. Svanberg; L. Swanson; J. Tedroff; S. Waters; N. Waters (S276).

P.1.c.037 Efficacy of intramuscular aripiprazole in the management of agitated patients by S. De Filippis; I. Cuomo; S. De Persis; M. Parisi; C. Di Pasquale; L. De Vecchis; L. Penna; A. Sciarretta (S272-S273).

P.1.c.032 Ropinirole as a coadjuvant treatment in the management of refractory patients with fibromyalgia: a case series by J.S. Vilchez; E.P. Calandre; F. Rico-Villademoros; R. Molina-Barea; C.M. Rodriguez-Lopez; J. Garcia-Carrillo (S270).

P.1.c.031 Tolerance effect to pregabalin in a subpopulation of fibromyalgia by K. Kosma; K. Kontoangelos; K. Roumbou; G. Papadopoulos; M. Anastasiou (S269-S270).

E.04.02 The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines by H. Grunze; E. Vieta; G. Goodwin; C. Bowden; R. Licht; H.J. Moeller; S. Kasper (S221-S222).

S.07.07 Slow frequency oscillations of response-time intra-subject variability in children with ADHD by N. Adamo; A. Di Martino; C. Peddis; E.X. Castellanos; A. Zuddas (S189).

S.07.08 Erythropoietin modulates emotional processing in biomarker models of antidepressant drug action in depressed patients by K. Miskowiak; E. Favaron; S. Hafizi; B. Inkster; P.J. Cowen; G.M. Goodwin; C.J. Harmer (S189-S190).

S.08.02 Role of Arc/Arg3.1 in the actions of psychostimulant drugs by F. Fumagalli; L. Cafflno; C. Franchi; M. Pasini; G. Racagni; M.A. Riva; L. Cervo (S190).

S.08.04 Learning about Arc/Arg3.1 and long-term memories by D. Kuhl; C. Gross; X.S. Mao; O. Ohana (S190-S191).

S.08.03 Arc/Arg3.1 synthesis and control of LTp consolidation in the adult dentate gyrus in vivo by C. Bramham; D. Panja; A. Tiron; R. Nair; K. Wibrand; S. Kuipers (S190).

S.07.05 Cannabis co-administration potentiates MDMA effects on temperature and heart rate by G. Dumont; C. Kramers; F. Sweep; D. Touw; J. van Hasselt; M. de Kam; J. van Gerven; J. Buitelaar; R.J. Verkes (S188).

S.07.04 Specific deletion of AMPA-R GluR1 subunits in D1 expressing neurons: cocaine-addiction related behavioural consequences by B. Halbout; M. Mameli; J. Rodriguez Parkitna; A. Bilbao; G. Schiitz; C. Lüscher; R. Spanagel (S188).

S.06.04 The dopamine system in adult ADHD – findings from the IMpACT study by B. Cormand; M. Ribasés; J.A. Ramos-Quiroga; C. Sánchez-Mora; M. Casas; S. Johansson; J. Haavik; A. Reif; B. Franke; M. Bayés (S186).

S.06.05 From synthesis to uptake – serotonergic genes in adult ADHD by J. Haavik; S. Johansson; P.M. Knappskog; I. Winge; J.A. McKinney; A. Halmeiy; E.T. Landaas (S186).

S.07.03 Effects of varenicline on dopamine D2/3 receptor binding in rats using ex vivo phosphor storage imaging by C.L. Crunelle; M.L. Miller; K. De Bruin; W. Van den Brink; J. Booij (S187).

S.12.03 Phosphodiesterase inhibitors as a target for enhanced cognition by A. Blokland; K. Rutten; O. Reneerkens; E. Bollen; J. Prickaerts (S195).

S.14.01 Is there a typical premorbid Parkinsonian personality? by T. Witjas; J.P. Azulay; A. Eusebio; J. Cohen; D. Magalon (S196).

S.12.02 The glycine transporter 1 and its involvement in memory by P. Singer; D. Boison; H. Mohler; J. Feldon; B.K. Yee (S194-S195).

S.09.03 Long acting naltrexone implants for heroin dependence by E. Krupitsky; E.E. Zvartau; G. Woody (S192).

S.10.03 Modulating the mineralocorticoid receptor as add-on therapy in antidepressant treatment with SSRI: a randomised controlled trial by C. Otte; K. Hinkelmann; S. Moritz; A. Yassouridis; H. Jahn; K. Wiedemann; M. Kellner (S193-S194).

S.06.02 From childhood to adulthood – testing the IMAGE candidates in IMpACT by B. Franke; S. Johansson; B. Cormand; J.A. Ramos-Quiroga; P. Asherson; S.V. Faraone; J.K. Buitelaar; K.P. Lesch; J. Haavik; A. Reif (S185).

S.06.01 Diagnostic assessment and multilevel phenotyping in the IMpACT study group by J.A. Ramos-Quiroga; R. Bosch; M. Casas (S184-S185).

S.02.02 Mood effects of DBS of the subthalamic nucleus: a role for 5-HT by T. Sharp; H. Hartung; S. Tan; P. Magill; A. Blokland; V. Visse-Vandevalle; H.W.M. Steinbusch; Y. Temel (S177).

S.02.05 Deep brain stimulation for treatment resistant depression – predictors of response by T.E. Schlaepfer; H.E. Bewernick; S. Kayser; D. Lenartz; V. Sturm (S178).

S.03.01 Do virus infections cause schizophrenia? by H. Karlsson; L. Asp; S.O. Ögren; S. Erhardt; M. Holtze; K. Kristensson; C. Dalman (S178).

S.01.01 Protein kinase C inhibitors in mania by A. Yildiz; D. Öngür; P.F. Renshaw (S175).

S.01.03 Treatment of bipolar disorders in children and adolescents by C. Moreno; J. Merchan-Naranjo; M. Alvarez; M. Giraldez; M. Parellada; D.M. Moreno; C. Arango (S176).

S.03.04 Inflammation and the glutamate system by N. Müller; A.M. Myint; M.J. Schwarz (S179-S180).

S.04.08 Serotonin-1A receptor binding potential in dorsal raphe nuclei predicts orbitofrontal reactivity in healthy subjects by A. Hahn; M. Savli; P. Stein; L.K. Mien; A. Holik; M. Mitterhauser; C. Windischberger; W. Wadsak; R. Lanzenberger; S. Kasper (S182-S183).

S.05.02 Early response as a response predictor: use of individual variability in clinical trials by B.J. Kinon; L. Chen; H. Ascher-Svanum; V. Stauffer; S. Kollack-Walker; W. Zhou; S. Kapur; J. Kane (S183).

S.05.03 The inherent trajectories in antipsychotic response: beyond simple responders and non-responders by S. Kapur; O. Arenovich; O. Agid; B. Muthen; L. Chen; B. Kinon (S184).

S.04.02 M- and T-tropic HIVs cause apoptosis in rat neuronal cell culture by F. Biggio; A. Bachis; I. Mocchetti (S180-S181).

S.15.01 Heart rate dynamics during conditioned fear in mice and its implications for affective disorders by O. Stiedl; J. Youn; R.F. Jansen; A.W. Pieneman; S.O. Ögren; M. Meyer (S197).

S.27.01 From animals to man: overview and main findings from the NewMood project by J.F.W. Deakin; G. Juhasz; I.M. Anderson; A. Payton; H. Platt; E. Pegg; D. Downey; I. Koychev; R. Elliott; K. Mekli (S214).

S.24.03 Amyloid plaque imaging in vivo by J. Seibyl; K. Marek (S211-S212).

S.24.02 The cell biology of Abeta generation by G. Multhaup; L. Muenter; A. Harmeier (S211).

S.22.04 Psychopharmacological treatment of impulsivity in personality disorders by S. Bellino; C. Rinaldi; P. Bozzatello; F. Bogetto (S209).

S.23.01 Genetic dissection of mouse avoidance behaviour: relevance for mood disorders by M.J.H. Kas; J.G. de Mooij-van Malsen; H.A. van Lith; G. Breen; D.A. Collier; B. Olivier (S210).

S.24.01 Paradigm shift in Abeta toxicity by T.A. Bayer; O. Wirths (S211).

S.27.02 Regulation of the raphe: adaptive and maladaptive responses to stress by L. Lanfumey; R. Mongeau; C. Martin; E. Paizanis; M. Hamon (S214).

S.27.03 Decreased VGLUT1 levels and long-term chronic mild stress: animal models addressing specific aspects of major depression by R.M. Tordera; A.L. Garcia-Garcia; N. Elizalde; E. Vénzala; M.J. Ramirez; J. Del Rio (S214-S215).

E.02.03 Efficacy markers in depression by C. Harmer (S219-S220).

E.02.04 PET and investigation of brain neurobiology by G. Knudsen; S.G. Hasselbalch (S220).

S.27.05 From gene to brain: neurotransmitter pathways to depression in humans by I.M. Anderson; G. Juhasz; R. Elliott; L.E.W. Deakin (S215).

S.17.03 Do changes in 5HT function underlie CBT efficacy in panic disorder? by C. Bell; J. Potokar; S. Hood; J. Nash; C. Frampton; D. Hince; S. Argyropoulos; D. Nutt (S201).

S.16.05 Animal models of cognitive flexibility by S. Granon; J.P. Changeux; P. Serreau (S200).

S.16.04 DISC1 mouse model of gene-environment interactions in schizophrenia by M. Pletnikov; Y. Ayhan; B. Abazyan; C. Pardo; A. Sawa; M. Vogel; C. Ross (S200).

S.15.03 Neuroendocrine function and sub-clinical atherosclerosis in healthy adults by M. Hamer; K. O'Donnell; A. Steptoe; A. Lahiri (S198).

S.16.02 Prefrontal cortex and attention by V.J. Brown; D.S. Tait (S199).

S.20.05 Peripheral and brain BDNF as a marker of mood disorder by F. Karege; J.M. Aubry; R. La Harpe; G. Bertschi; A. Malafosse (S206).

S.21.02 Efficacy and safety of antipsychotics in early onset psychosis by M. Parellada; C. Arango; D. Moreno; M. Alvarez; C. Moreno; D. Fraguas (S207).

S.21.03 Antipsychotics for non-psychotic disorders by A. Zuddas; S. Paba; T. Usala (S207).

S.20.04 Consequences of altered BDNF protein levels on hippocampal serotonin neurotransmission and behaviour by A. Gardier; T. Deltheil; K. Tanaka; C. Reperant; R. Hen; D.J. David; B. Guiard (S205-S206).

P.2.a.052 Use of antidepressants in the treatment of major depressive disorder in an outpatient mental health center by C. Gamier; B. Díaz; P. Alvaro; R. Sanchís; J. Castaño; D. Coreóles; L.M. Martín; A. Bulbena (S390-S391).

P.2.b.001 Abnormalities of trace elements in depressed patients using hair analysis by H.M. Sung; J.B. Kim; S.W. Jung; I.H. Shin; Y.W. Kim (S391).

P.2.b.003 Endothelial dysfunction in a rodent model of depression may underlie atherosclerosis formation by E. Isingrini; J.L. Freslon; M.C. Machet; V. Camus; C. Belzung (S392).

P.2.a.050 Post traumatic brain injury major depression and primary major depression: psychopathological and neuropsychological profiles by M.C. Mauri; A. Colasanti; S. Paletta; L.E. De Gaspari; D. Moliterno; G. Panza; G. Miserocchi; A.C. Altamura (S389).

P.2.a.049 Functional outcome after 12 months of deep brain stimulation for treatment resistant major depressive disorder by S.J. Rizvi; S.H. Kennedy; H. McNeely; P. Giacobbe; H.S. Mayberg; A.M. Lozano (S388-S389).

P.2.a.043 Psychoticism dimension in a population of patients with non-psychotic major depression disorder by V. Mantua; S. Calugi; E. Schiavi; M. Miniati; G.B. Cassano (S385).

P.2.a.047 A comparison of rating quality between subtitled and spoken Hamilton depression rating scale interviews by B. Friedmann; E. Braxton; H. Riordan; C.J. Weber; M.F. Murphy; N.R. Cutler (S387-S388).

P.2.b.005 Magnetisation imaging in major depressive disorder by N. van der Wee; C. Boersma; M. van Buchem; J. Milles; M.J. van Tol; A. Alemán; R. Demanescu; D. Veltman; F. Zitman (S393-S394).

P.2.b.006 Valence-specific frontal hypoactivation during word recognition in major depressive disorder by N. van der Wee; M.J. van Tol; L. Melby; M. Nielen; A. Alemán; L. Demenescu; M. van Buchem; F. Zitman; D. Veltman (S394).

P.2.b.016 Differential effect of serotonergic and noradrenergic antidepressants on brain activation during cognitive control task by G. Wagner; U. Pietsch; G. Peikert; C. Schachtzabel; K. Koch; J.R. Reichenbach; H. Sauer; R.G. Schlosser (S400).

P.2.b.015 Whole brain resting-state analysis reveals decreased connectivity in major depressive disorder by I. Veer; N. van der Wee; C. Beckmann; E. Baerends; M. van Tol; L. Ferrarini; J. Milles; A. Alemán; D. Veltman; S. Rombouts (S399-S400).

P.2.b.018 Genes differentially expressed in CB1 knockout mice: involvement in the depressive-like phenotype by E. Aso; A. Ozaita; A. Busquets; M.A. Serra; R. Maldonado (S401-S402).

P.2.b.014 Four days of citalopram increase in vitro glucocorticoid receptor function in healthy volunteers by L. Carvalho; M.F. Juruena; A.S. Papadopoulos; L. Poon; A.J. Cleare; C.M. Paríante (S399).

P.2.b.013 Social isolation and "depressed" Flinders Sensitive Line rats: behaviour, steroids, and neuronal plasticity markers by M. Bianchi; N. Ladurelle; P. Liére; A. Pianos; A.A. Mathé; E.E. Baulieu (S398).

P.2.b.008 Metabotropic glutamate receptor 5: role in depression? by A. Deschwanden; S.M. Ametamey; A. Johayem; G. Westera; Y. Auberson; A. Buck; G. Hasler (S395-S396).

P.2.b.007 Pain and depression: occurrence of pain among patients with mild and moderate depression by K. Krysta; K. Pasternak; P. Prucnal; I. Irena Krupka-Matuszczyk (S394-S395).

P.2.b.009 The association of pain vigilance and awareness with subclinical depression by D. Pap; G. Xenia; J. Lazary; A. Benko; E. Molnar; G.Y. Bagdy (S396).

P.2.b.010 Evaluating nociceptive behaviour in the Wistar Kyoto rat model of depression by P. Calpin; N. Burke; D.P. Finn; M. Roche (S396-S397).

P.2.b.012 Long-term neurobiological changes by chronic mild stress and residual alterations after antidepressant discontinuation by N. Elizalde; A.L. Garcia-Garcia; S. Totterdell; N. Gendive; E. Vénzala; M.J. Ramirez; J. Del Rio; R.M. Tordera (S397-S398).

P.2.b.01l A new preclinical model of vulnerability to depression-like behaviours by A. Blugeot; B. Zeau; C. Rivat; C. Becker; J.J. Benoliel (S397).

P.2.a.042 Comparison of six antidepressants in terms of time to discontinuation by V. Karabulut; Y.C. Cengiz; B. Ozcelik; R. Onem; A. Tekin; O. Tankaya; G. Alpak; O. Karamustafalioglu (S384-S385).

P.2.a.041 Duration of untreated illness (DUI) in first-depressive episodes: the earliest treatment, the better outcomes by J. De Diego-Adeliño; M.J. Portella; D. Puigdemont; R. Pérez-Egea; R. Morgan-Ferrando; E. Álvarez; V. Pérez (S384).

P.2.a.021 Insomnia as a predictor of depression in UK primary care by F. de Vries; A.M. Gallagher; M.H. Lader; A.T. Tylee; J. Donoghue; S.M. Cockle; T.P. van Staa; D.J. Nutt (S372-S373).

P.2.a.022 Comorbidity between depression, anxiety disorders and infertility: effect on quality of life in Egyptian women by D.N. Radwan; H. Ramy; A. Elmissiry; K.H. Moussa; M. Elsayed; M. Mansour; A. Khalil (S373).

P.2.a.023 Gender differences in symptoms and comorbidity patterns in Dutch depressive outpatients: the Leiden Routine Outcome Monitoring (ROM) Study by N. van der Wee; M.S. van Noorden; E. Giltay; M. den Hollander-Gijsman; R. van der Lem; Y. Rood; E.G. Zitman (S373-S374).

P.2.a.025 Neural effects of 7-day anti-depressant treatment on reward by C. McCabe; P.J. Cowen; C.J. Harmer (S374-S375).

P.2.a.024 Alcohol use disorder and its associations with polymorphisms on ALDH2, BDNF, 5-HTTLPR and MTHFR in older Korean men by J.M. Kim; K.Y. Bae; J.A. Yoo; I.S. Shin; S.W. Kim; S.J. Yang; T. Youn; K.H. Chung; J.S. Yoon (S374).

P.2.a.019 Decreased fronto-limbic gray matter volume associated with recurrent major depressive disorder by D. Arnone; E.J. Pegg; S. McKie; D. Downey; R. Elliott; S.R. Williams; J.F.W. Deakin; I.M. Anderson (S371).

P.2.a.018 Persistence and compliance to antidepressant treatment in patients with depression: a chart review by N. Sawada; H. Uchida; T. Suzuki; K. Watanabe; T. Kikuchi; S. Nio; T. Tsuboi; T. Handa; H. Kashima (S370-S371).

P.2.a.017 Fatigue questionnaire: sensitivity to changes in depression severity in depressed patients by P. Ferentinos; V.P. Kontaxakis; B. Havaki-Kontaxaki; D. Dikeos; G.N. Papadimitriou (S370).

P.2.a.016 Increased neural responses to sad facial expressions in current but not remitted major depression by D. Amone; E.J. Pegg; S. McKie; D. Downey; R. Elliott; S.R. Williams; I.M. Anderson (S369-S370).

P.2.a.026 Meta-analysis of region of interest studies in unipolar depression and bipolar disorder by D. Arnone; A.M. Mclntosh; K.P. Ebmeier; J.M. Anderson (S375).

P.2.a.035 Persistence with hypnotics in depressed patients treated in UK primary care by A.M. Gallagher; F. De Vries; J. Donoghue; D.J. Nutt; A.T. Tylee; S.M. Cockle; T.P. van Staa; M.H. Lader (S380-S381).

P.2.a.037 The efficacy and safety of milnacipran 50 mg bid in patients with major depression: the results of a clinical trial by A. Gogus; T. Oral; O. Berksun; O. Karamustafalioglu; S. Vahip; Z. Tunca; O. Yazici (S381-S382).

P.2.a.038 The prevalence of major depressive disorder and bipolar disorder in freshmen assessed by self reported screening test by K.J. Min; W.M. Bahk; Y.C. Shin; B.H. Yoon; D.I. Jon; J.H. Song; E.H. Hur; B.S. Choi (S382).

P.2.a.040 Effects of magnetic seizure therapy and electroconvulsive therapy in treatment-resistant depression by S. Kayser; B.H. Bewernick; C. Grubert; B. Hadrysiewicz; A. Koch; J. Grofle Bley; N. Axmacher; T. Schlaepfer (S383).

P.2.a.034 The risk of suicide and suicidal ideation in depressed patients with sleep disturbance by A.M. Gallagher; F. De Vries; A.T. Tylee; M.H. Lader; J. Donoghue; S.M. Cockle; T.P. van Staa; D.J. Nutt (S379-S380).

P.2.a.033 Initiation of hypnotics or anxiolytics in depressed patients treated in UK primary care by A.M. Gallagher; F. De Vries; D.J. Nutt; J. Donoghue; A.T. Tylee; S.M. Cockle; T.P. van Staa; M.H. Lader (S379).

P.2.a.028 Acute and chronic effects of naturalistically smoked cannabis on depression and anxiety by T.P. Freeman; C.J.A. Morgan; G. Schafer; H.V. Curran (S376).

P.2.a.03l A cross-cultural, comparative study of the prevalence and symptom patterns of depression among college students by R. Parikh; S. Sonawalla; S. Sharma-Pandey; A. Farabaugh; A. Yeung; S. Safren; M. Fava (S378).

P.2.a.032 Resource use in depressed patients with sleep disturbance by A.M. Gallagher; F. De Vries; D.J. Nutt; J. Donoghue; A.T. Tylee; S.M. Cockle; T.P. van Staa; M.H. Lader (S378-S379).

P.2.b.021 First characterisation of tryptophan hydroxylase-2 (Tph2) knockout mice by L. Gutknecht; J. Waider; S. Merker; L. Lanfumey; M. Hamon; K.P. Lesch (S403).

P.2.c.001 Paroxetine for the treatment of old age depression: a systematic review by S. Curran; R. Rampat; R. Spencer; V. Minogue; J. Wattis (S403-S404).

P.2.c.043 Modeling and simulation to optimise efficacy and tolerability for a once-a-day trazodone formulation by V. Lemaire; C. Benquet; D. Le Garree; S. Robertson; D. Smith; S. Stahl (S428).

P.2.c.042 Effects of escitalopram on the modulation of the identification of facial expressions by healthy women: a fMRI study by C.M. Del-Ben; A. Sponholz; R. Shuhama; S. McKie; J.F.W. Deakin; F.G. Graeff (S427-S428).

P.2.c.045 Outcome of escitalopram treatment based on baseline severity of depression by S. Stamouli; V. Lagari; A. Liakouras; P. Grigoriou; P. Piperos; D. Giailoglou (S429).

P.2.d.001 Dose-dependent effects of caffeine in a chronic mild stress model of depression in ICR mice by J. Tchekalarova; D. Pechlivanova; V.V. Petkov; R. Nikolov; K. Yakimova (S430).

P.2.c.041 Biomarkers for the combined efficacy of cognitive behavioural therapy in antidepressant treatment in depression by A. Nocon; K. Hackmann; H. Pfister; B. Heldmann; M. Rosenhagen; S. Lucae; M. Ising (S427).

P.2.c.034 Prefrontal metabolic abnormalities in major depressive disorder: a proton magnetic resonance spectroscopy study by M.J. Portella; R. Morgan-Ferrando; B. Gómez-Ansón; J. De Diego-Adeliño; D. Puigdemont; R. Pérez-Egea; E. Álvarez; J. Ruscalleda; V. Pérez (S423-S424).

P.2.c.033 Psychotropic medication in Spanish population setting: treatment adequacy for major depressive disorder by M. Blanca-Tamayo; A. Sicras-Mainar; B. Pascual-Arce; M.C. Pérez-Navarro; R. Navarro-Artieda; L. García-Sánchez; N. Muro-Perea (S422-S423).

P.2.c.036 Increase of 5-HTT occupancy during escitalopram or citalopram treatment correlates with antidepressant efficacy in major depressive disorder by E. Akimova; M. Savli; D. Haeusler; M. Fink; A. Hahn; W. Wadsak; M. Mitterhauser; R. Lanzenberger; K. Kletter; S. Kasper (S424-S425).

P.2.c.038 Duloxetine versus placebo in patients with major depressive disorder (MDD): assessment of energy and vitality in MDD by T.M. Myers-Oakes; M.E. Thase; A.L. Meyers; J. Ahl; A. Prakash; L.B. Marangell (S425-S426).

P.2.d.004 S41744, a dual NK1 antagonist/5-HT reuptake inhibitor and antidepressant: a comparison to aprepitant and paroxetine by M. Broceo; A. Gobert; C. Mannoury la Cour; A. Dekeyne; G. De Nanteuil; B. Olivier; T.R. De Jong; T.I. Cremers; G. Flick; M.J. Millan (S432).

P.2.d.012 Ketamine, memantine and traxoprodil for treatment of depression: in vivo neurochemical mechanism of action by G.N. Smagin; D. Song; H. Wang; J.J. Doherty; V.S. Palamarchouk (S436-S437).

P.2.d.014 Evaluation of the antidepressant effect of new synthesized alpha2-adrenoceptor antagonists by C. Muguruza; F. Rodriguez; J.E. Ortega; L. Urigiien; J.J. Meana; I. Rozas; L.F. Callado (S437-S438).

P.2.d.015 Tissue type plasminogen activator gene polymorphisms and mirtazapine responses in Koreans with major depression by M.S. Lee; H.S. Chang; H.Y. Lee; J.H. Paik; B.J. Ham; R.H. Kang; Y.J. Jeong; H.M. Kim (S438).

P.2.d.017 Pharmacological profile of Lu AA21004, a novel multi-target drug for the treatment of mood disorders by A. Mørk; L.T. Brennum; S. Fallón; S. Bisulco; K. Frederiksen; B. Bang-Andersen; A.B. Lassen; H. Zhong; C. Sanchez; T.B. Stensbøl (S439).

P.2.d.010 Single and chronic agomelatine treatment differently affect cerebral a1-adrenergic receptors by I. Nalepa; K. Wieczerzak; M. Kowalska; D. Nawrat; J. Vetulani (S435-S436).

P.2.d.006 Use of antidepressants and the risk of the metabolic syndrome: the Netherlands Study of Depression and Anxiety (NESDA) by A.K.B. van Reedt Dortland; E.J. Giltay; T. van Veen; F.G. Zitman; B.W.J.H. Penninx (S433).

P.2.d.005 Effects of chronic treatment with 7-nitroindazole on rat hippocampal gene and protein expression after swimming stress by F. Ferreira; S. Joca; D. Pinheiro; A. Santos; W. Silva; A. Catalan; L. Greene; F. Guimaraes (S432-S433).

P.2.d.007 Reversible inactivation of the medial prefrontal cortex induces antidepressant-like effects in rats by F.S. Guimaraes; A.A. Scopinho; M.A. Scopinho; F.M.A. Correa; S.R.L. Joca (S433-S434).

P.2.d.008 Platelet markers before and after trazodone in depressed patients by D. Marazziti; G. Consoli; M. Picchetti; F. Golia; S. Silvestri; S. Baroni; I. Másala; M. Carlini; L. Dell'Osso (S434).

P.2.d.009 Differential effects of fluoxetine or venlafaxine treatment on maternal separation, an experimental model of depression by E. Martisova; B. Aisa; R. Tordera; B. Lasheras; J. Del Rio; M.J. Ramirez (S434-S435).

P.2.c.011 Duloxetine modulates pain-related brain response in patients with major depressive disorder by N. Cardoner; M. López-Sola; J. Pujol; R. Hernández-Ribas; J. Deus; H. Ortiz; B.J. Harrison; C. Soriano-Mas; E. Martinez_Amoros; J.M. Menchon (S409-S410).

P.2.c.010 Duloxetine for pathological laughing and crying in amyotrophic lateral sclerosis by P. Ferentinos; T. Paparrigopoulos; M. Rentzos; V. Zouvelou; I. Evdokimidis (S409).

P.2.c.012 Chronic SSRI treatment modifies blood oxygen level-dependent (BOLD) responses to emotional face expressions by D. Downey; K.E. Davies; S. McKie; G. Juhasz; I.M. Anderson; M.A. Smith; J.F.W. Deakin; S.R. Williams (S410).

P.2.c.013 Two generic antidepressant medications and their bio-equivalence or bio-inequivalence by F. Chenu; L. Batten; G. Zernig; E. Ladstaetter; C. Hebert; P. Blier (S411).

P.2.c.015 Efficacy of SSRIs in treating depression in patients with ischaemic heart disease, a meta-analysis by A.K. Barakzai; A.E. Ades; G. Lewis; X. Qian; S.J.C. Davies (S412).

P.2.c.014 Duloxetine in the treatment of depression comorbid with anxiety: a pilot study with 12-month outcomes by R. Bassetti; M.F. Bosi; A. Colombo; A. Roaro; R. Truzoli; G. Ba (S411-S412).

P.2.c.009 Duloxetine versus iv citalopram in partial/non responder depressed patients: a randomized placebo-controlled study by B. Dell'Osso; M. Buoli; A. Albano; S. Bortolussi; B. Benatti; I. Balossi; L. Oldani; A.C. Altamura (S408-S409).

P.2.c.002 Serotonin or noradrenalin reuptake inhibition in seasonal affective disorder: escitalopram versus reboxetine by E. Pjrek; A. Konstantinidis; E. Assem-Hilger; N. Praschak-Rieder; M. Willeit; S. Kasper; D. Winkler (S404).

P.2.c.004 Basic fibroblast growth factor (FGF2) gene polymorphisms could contribute to SSRIs treatment response and tolerability by M. Kato; G. Okugawa; M. Wakeno; Y. Takekita; S. Nounen; S. Tetsuo; J. Azuma; A. Serretti; T. Kinoshita (S405-S406).

P.2.c.007 Benefits of switching antidepressants following early nonresponse by S. Nakajima; H.U. Uchida; T.S. Suzuki; H.T. Takeuchi; K.N. Nomura; K.W. Watanabe; H.K. Kashima (S407).

P.2.c.017 Patients' behaviours towards side effects of antidepressants with a focus on gender-difference by T. Kikuchi; H. Uchida; T. Suzuki; R. Kitahata; J. Hirano; M. Tomita; K. Watanabe; H. Kashima (S413-S414).

P.2.c.029 Suicide risk and choice of antidepressant by M. Agius; R. Zaman; M. Gilhooley; A. Davis (S420-S421).

P.2.c.024 024 Association study between BDNF genetic polymorphism and treatment responses of SSRI in major depressive disorder by Y. Lee; Y. Jung; J. Park; S. Kim; J. Kim; C. Kang; B. Lee; D. Lee (S417-S418).

P.2.c.019 Lamotrigine use for unipolar depression in Korea by H. Sim; E. Kang; D. Lee (S414-S415).

P.2.c.018 Moclobemide dosage regimen adjustment in depressive patients on carbamazepine co-therapy by A. Rakic Igniatovic; B. Miljkovic; D. Todorovic; I. Timotijevic; M. Pokrajac (S414).

P.2.c.020 Hidden partial non-compliance with antidepressants and its effect on treatment response by M. Reis; A.C. Åkerblad; L. von Knorring; L. Ekselius (S415).

P.2.c.021 Efficacy and safety of combined therapy with moclobemide and valproic acid or carbamazepine in depressive patients by M. Todorovic; A. Rakic Ignjatovic; B. Miljkovic; D. Todorovic; I. Timotijevic (S415-S416).

P.2.c.022 Efficacy of trazodone in patients with primary insomnia with and without concomitant depressive symptomatology by A. Wichniak; W. Jernajczyk; A. Wierzbicka; A. Sobianska; E. Szatkowska; K. Czasak; I. Musinska (S416).

R2.a.01l Risk factors of treatment resistance in major depression: results of multicenter TRES-DEP study by D. Dudek; J.K. Rybakowski; M. Siwek; T. Pawlowski; D. Lojko; A. Kiejna (S366-S367).

P.1.e.033 Subgenual cingulate volumes in offspring of bipolar parents by T. Novak; T. Hajek; M. Kopecek; E. Gunde; M. Alda; C. Hoschl (S319).

P.1.f.002 Plasma BDNF levels of patients with somatisation disorder and their alterations after pharmacotherapy by J.C. Yang; T.W. Park; Y.C. Chung; S.K. Chung; A.J. Jung; Y.K. Kim (S320).

P.1.g.002 Early course of disease, current cognitive and clinical status in chronic schizophrenia by A. Kalwa; M. Rzewuska; A. Pirog- Balcerzak; M. Luks; J. Skalska (S321).

P.1.g.00l Switch to lamotrigine due to adverse events following antiepileptic treatment by P. Corti; M.E. Gaspard; P. Bousquet; D. Strubel (S321).

P.1.e.031 Effect of EMDR treatment in PTSD patients: clinical and biological outcomes are stable in 1-year follow-up by M. Tavanti; L. Bossini; S. Calossi; F. Fanetti; D. Marino; G. Vatti; F. Pieraccini; P. Castrogiovanni; A. Fagiolini (S318).

P.1.e.030 Structural and metabolic abnormalities in bipolar I vs II disorder from combined voxel-based morphometry MRI and (18)F-fluorodeoxyglucose PET brain imaging by T. Su; C.T. Cheng-Ta Li; L.F. Li-Fen Chen; Y.S. Yong-Shen Chen; S.J. Shyh-Jen Wang; J.C. Jen-Chuen Hsieh (S317-S318).

P.1.e.025 Effects of the Amazonian psychoactive plant beverage ayahuasca on prefrontal and limbic regions during a language task: a fMRI study by D. Almeida Prado; J. Pinto; J. Crippa; A. Santos; S. Ribeiro; D. Araujo; A. Zuardi; C. Chaves; J. Hallak (S314-S315).

P.1.e.024 D2 receptor occupancy with HC-raclopride PET following single and multiple dose: does steady state make a difference? by M. Schmidt; E. Mannaert; P. De Boer; D. William; M. Neyens; T. van Iersel; A. Willemsen (S314).

P.1.e.026 Resting state connectivity between amygdala and orbitofrontal cortex reflects state anxiety in social phobia by P. Stein; A. Weissenbacher; A. Hahn; F. Gerstl; C. Windischberger; E. Moser; S. Kasper; R. Lanzenberger (S315).

P.1.e.027 Psychotic symptoms and relation to periventricular brain lesions in patients with multiple sclerosis by P. Kostaras; G. Moussas; A. Tselebis; F. Karra; M. Maltezou (S315-S316).

P.1.e.029 Cerebral volumetry in patients with systemic lupus erythematosus presenting neuropsychiatric manifestations by P. Louzada-junior; R. Oliveira; M.s. Carlos; L. Wichert-ana; A.c. Santos (S317).

P.1.e.028 Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients by S. Potkin; D. Keator; J. Mukherjee; A. Preda; D. Highum; A. Gage; J. Xie; P. Ghahramani; I. Laszlovsky (S316).

P.1.g.003 Theory of mind deficits in unaffected relatives of patients with schizophrenia and bipolar disorder by M.O. Yucel; H. Devrimci-Ozguven; E.T. Ozel-Kizil; S. Haran; M.C. Saka; E.C. Atbasoglu (S322).

P.1.g.014 Effectiveness of cognitive behavioral therapy for comorbid obsessive compulsive disorder in patients with psychosis by A. Tundo; L. Salvati; D. Di Spigno; A. Parena; L. Cieri; S. Sciortino (S327-S328).

P.1.g.016 Sleep deprivation-induced memory deficits in mice: role of state-dependency by C.L. Patri; L. Sanday; K.A. Zanin; J.M.C. Leite; T.F. Trombin; S.R. Kameda; M.L. Andersen; S. Tufik; R. Frussa-Filho (S329).

P.1.g.018 Tenses can have different effects on declarative processes by O.M. Koçak; S. Yüksel; A. Yilmaz; E. Eren-Kocak; K. Sayar (S330).

P.1.g.017 Sodium fluoride induced memory impairment is associated with changes in striatal monoaminergic levels by E.M. Losso; M. Pereira; P.A. Dombrowski; C. Da Cunha; R. Andreatini (S329-S330).

P.1.g.006 TMS over the dorsal visual pathway generates schizophrenia-like visual-deficit in healthy controls by R. Amiaz; A. Gershon; D. Vainiger; M. Weiser; M. Lavidor; D.C. Javitt (S323-S324).

P.1.g.005 Protective effect of new l-valine derivatives on brain function in experimental model of aggression in mice by E. Encheva; M. Novoselski; L. Tancheva; V.V. Petkov; S. Stancheva; L. Alova; D. Tsekova (S323).

P.1.g.009 Psychomotor performance, fatigue, sleepiness and cognitive function in in-patients with major depression by D. Neu; X. Montana; Y.M. Vandriette; C. Kornreich; P. Peigneux; P. Verbanck; P. Linkowski; O. Le Bon (S325-S326).

P.1.e.022 Effect of bupropion on extracellular dopamine levels in the striatum: a translational PET approach by A. Egerton; J.P. Shotbolt; P.R. Stokes; O.D. Howes; P.M. Grasby (S313).

P.1.e.023 Longitudinal assessment of presynaptic dopamine function in the striatum: a [18]F-DOPA PET test-retest study by A. Egerton; A. Demjaha; P.M. Grasby; P.K. McGuire; R.M. Murray; O.D. Howes (S313-S314).

P.1.e.002 Changes in brain perfusión in drug-naive panic patients with SPECT following cognitive-behavioural therapy by J.B. Kim; W.H. Nam; J.H. Chae; E.J. Chang; S.Y. Ryu; K.S. Won; S.K. Zeon; Y.A. Chung; H.M. Sung (S300-S301).

P.1.e.00l A dynamic [18F]-fally pride PET study: measuring dopamine neuromodulation in the extrastriatal reward circuit by E. Vrieze; J. Ceccarini; D. Pizzagalli; G. Bormans; K. Demyttenaere; K. Van Laere; S. Claes (S300).

P.1.e.004 Chronic stress and antidepressant treatment have opposite effects on P-glycoprotein at the blood-brain barrier by O. de Klerk; F.J. Bosker; J.A. den Boer; A.T.M. Willemsen; A. van Waarde; P. Meerlo (S302).

P.1.e.006 Regional increase in P-glycoprotein function in the blood-brain-barrier of patients with chronic schizophrenia by O.L. de Klerk; A.T.M. Willemsen; F.J. Bosker; A.L. Bartels; N.H. Hendrikse; J.A. den Boer (S303).

P.1.d.016 Jy-xhe-053, a benzodiazepine ligand less efficacious at GABAA receptors containing alphal and alpha5 than alpha2 and alpha3 subunits by M.M. Milinkovic; M.M. Savic; S. Huang; R. Furtmüller; S. Majumder; J. Samardic; J.M. Divljakovic; B.L. Roth; W. Sieghart; J.M. Cook (S296).

P.1.d.015 Behavioural and molecular correlations in the rat chronic mild stress model of depression by O. Wiborg; K. Henningsen; E. Bouzinova; T. Christensen; S. Christiansen (S295-S296).

P.1.d.017 Blockade of 5-alpha reductase reduces compulsive behaviors in mice by V. Bini; R. Frau; M. Collu; S. Paba; P. Devoto; F. Marrosu; M. Bortolato (S296-S297).

P.1.d.018 WYS-8, a novel ligand at GABAA receptors: a step forward to linking in vitro with in vivo selectivity? by S.M. Joksimovic; M.M. Savic; M.M. Milinkovic; M. Van Linn; J. Ramerstorfer; S. Majumder; W. Yin; B.L. Roth; W. Sieghart; J.M. Cook (S297).

P.1.e.017 Chronic SSRI treatment induces adaptive changes in brain 5-HT phMRI responses by D. Downey; K.E. Davies; S. McKie; G. Juhasz; I.M. Anderson; M.A. Smith; J.F.W. Deakin; S.R. Williams (S309-S310).

P.1.e.016 Proton magnetic resonance spectroscopy study in first-episode and chronic schizophrenic patients by B. Galinska; A. Szulc; E. Tarasow; B. Kubas; B. Konarzewska; N. Waszkiewicz (S309).

P.1.e.019 Imaging gender differences in serotonin-1A receptor lateralization in language areas of healthy subjects using PET by M. Fink; M. Lanzenberger; M. Savli; C. Spindelegger; M. Mitterhauser; W. Wadsak; P. Stein; A. Hahn; K. Kletter; S. Kasper (S311).

P.1.e.02l The effects of cognitive-behavioural therapy on brain regional cerebral blood flow in obsessive compulsive disorder by G. Berk; B.M. Ergun; Y. Narin; C. Basoglu; A.S. Gonul; S. Ebrinc; M. Cetin; M.Z. Sungur (S312).

P.1.e.020 Brain metabolite alterations in subjects at ultra-high risk for psychosis: magnetic resonance spectroscopy study by M. Byun; J. Choi; S. Yoo; D. Kang; C. Choi; D. Jang; W. Jung; J. Lee; J. Kwon (S311-S312).

P.1.e.015 Involvement of the endocannabinoid system in associative memory: a pharmacological MRI study by M.G. Bossong; H.H. Van Hell; G. Jager; A. Brouwer; R.S. Kahn; N.F. Ramsey (S308-S309).

P.1.e.014 The acute effects of delta-9-tetrahydro-cannabinol (THC) on brain activity during working memory by H.H. van Hell; M.G. Bossong; G. Jager; E. Saliasi; R.S. Kahn; N.F. Ramsey (S308).

P.1.e.010 Understanding postpartum blues: a time course of MAO-A levels in the living human brain during the postpartum period by J. Sacher; A.A. Wilson; P. Rusjan; S. Hassan; L. Jacobs; P.M. Bloomfield; D.E. Stewart; S. Houle; J.H. Meyer (S305-S306).

P.1.e.009 The disrupted-in-schizophrenia-1 ser704cys polymorphism and brain morphology in schizophrenia by M. Suzuki; T. Takahashi; M. Tsunoda; N. Maeno; Y. Kawasaki; S. Zhou; H. Tsuneki; S. Kobayashi; M. Kurachi; N. Ozaki (S305).

P.1.e.011 Clinical correlates of brain metabolite measures in chronic schizophrenia by A. Szulc; B. Galinska; E. Tarasow; B. Kubas; B. Konarzewska; N. Waszkiewicz; R. Poplawska (S306).

P.1.e.013 Lorazepam impairs processing of frequency changes andnovel sounds: combined MEG/EEG study by S. Kahkonen; E. Pekkonen; P. Horn; J. Huttunen; R. Kivisaari; M. Korostenskaja (S307-S308).

P.1.h.001 Delayed sleep phase syndrome in burn patients by B.C. Lee; B.W. Lee; J.E. Park; I.Y. Kim (S331).

P.1.i.036 Genetic association with impaired decision-making and personality traits in suicide attempters by A. Szkaliczki; E. Krivek; B. Ando; A. Fehér; Z. Janka; P. Almos (S355).

P.1.i.035 Objective and subjective efficacy of ramelteon 4mg in adults with chronic insomnia by G. Hajak; L. Ferini-Strambi; S. Wang-Weigand; E. Waldron; T. Roth (S354-S355).

P.1.i.038 Long-term safety and efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder by R. Lasser; R. Weisler; J. Young; G. Mattingly; J. Gao; L. Adler; L. Squires (S356).

P.1.i.040 Increased expression of diabetic autoantigen PTPR-N in basal ganglia of Tourette's syndrome patients by A. Morer; W. Chae; Z. Tobiasova; O. Henegariu; F. Vaccarino; A. Bothwell; J.F. Leckman; I. Kawikova (S357).

P.1.i.034 Efficacy outcomes during longterm prolonged-release methylphenidate treatment of adults with ADHD by L. Imhof; H.J. Nyerod; H.J. Filipe; J. Dejonckheere; S. Wachter; B. Schauble; J. Buitelaar; S. Kooij; M. Casas; J.C. Van Oene (S353-S354).

P.1.i.025 Vasopressin as stimulator of the cancerous growth metastases by A. Amikishieva; S.I. Ilnitskaya; N.A. Popova; V.P. Nikolin; M.D. Belyaev; T.G. Tolstikova; V.I. Kaledin (S350).

P.1.i.024 Arnold-Chiari type I malformation with psychiatric symptoms: a case report by F.O. Orhan; Z. Yuksel; O. Altunoren; I. Altun; S. Berk; O. Akman; M.F. Karaaslan (S349-S350).

P.1.i.029 Pharmacist interventions involving psychotropic medication in inpatient pharmacotherapy by B. Pascual Arce; N. Muro-perea; M. Blanca-tamayo; M.c. Pérez-navarro; L. García-sánchez; A. Sicras-maynar (S351-S352).

P.1.i.0311 Predictors of treatment outcome with long-acting methylphenidate in attention deficit hyperactivity disorder in adults by J.A. Ramos-Quiroga; S. Kooij; G.E. Trott; J.R. Medori; J. Dejonckheere; J.C. van Oene; B. Schauble; M. Casas; J. Buitelaar (S352-S353).

P.1.i.041 Sport, physical health and lyfestyle in psychiatric illness by L. Ferrannini; C. Venturino; C. Pitto; M. Ferrari; P. Greco (S357-S358).

P.2.a.005 Serum BDNF levels correlate with hippocampal volumes in first episode, medication-free depressed patients by M. Eker; O. Kitis; F. Taneli; O.D. Ekec; E. Ozan; K. Yucel; K. Coburn; A.S. Gonul (S363).

P.2.a.004 A comparative study on alexithymia in depressive, somatoform, anxiety, and psychotic disorders among Koreans by S.J. Lee; H.D. Rim; H. Jo; S.H. Jeong; Y.H. Lee; U.S. Chung; J.J. Lee; J.M. Woo; Y.W. Park (S362-S363).

P.2.a.007 Screening for depression during pregnancy by A. Bunevicius; L. Kusminskas; V.J. Pop; C. Pedersen; R. Bunevicius (S364-S365).

P.2.a.009 Prediction of response to serotonin reuptake inhibitors in patients with depression: QEEG cordance value as a predictor by M. Bares; M. Brunovsky; T. Novak; M. Kopecek; P. Stopkova; P. Sos; V. Krajca (S365-S366).

P.2.a.008 Right-sided, 1-Hz repetitive TMS compared with venlafaxine extended-release in the treatment of resistant depression: a double-blind study by M. Bares; M. Kopecek; T. Novak; P. Stopkova; P. Sos; J. Kozeny; M. Brunovsky; C. Hóschl (S365).

P.2.a.003 Prescription pattern and side effect profiles of bupropion by W.M. Bahk; K.U. Lee; D.I. Jon; K.J. Min; Y.C. Shin; Y.S. Woo; C.H. Kim (S362).

P.1.i.044 Evaluation of cognitive functioning in young, professionally active men after coronary bypass by A. Woznica; L.J. Krzych; A. Pawlak; J. Skarysz; Z. Eysymontt; I. Krupka-Matuszczyk; K. Krysta; A. Bochenek; M. Cisowski (S359).

P.1.i.043 Protective personality factors associated with premenstrual symptomatology in healthy women by X. Gonda; T. Telek; D. Pap; G. Csukly; K.N. Fountoulakis; H.G. Kiss; G. Bagdjr (S358-S359).

P.1.i.045 Lesion and stimulation of the mesolimbic motivational dopamine system influence peripheral blood lymphocyte number by K. Plucinska; B. Grembecka; W. Glac; P. Badtke; G. Jerzemowska; D. Myslinska; D. Wrona (S359-S360).

P.1.i.046 C-reactive protein gene polymorphisms are associated with cortisol awakening response by G. Veen; E.J. Giltay; R.H. de Rijk; I.M. van Vliet; E.G. Zitman (S360).

P.2.a.00l Antidepressive therapy effects on emotional cognition in elderly depressed patients by E. Savaskan; S.E. Miiller; A. Bohringer; A. Schulz; H. Schachinger (S361).

P.1.i.022 High level of TV viewing is associated with silent inflammation by J. Korkeila; J. Markkula; P. Korhonen (S348-S349).

P.1.i.003 Chain reactions: polyunsaturated fatty acids and the depressive phenotype in maternally separated rodents by G. Clarke; S.M. O'Mahony; P. Ross; C. Stanton; J.F. Cryan; T.G. Dinan (S337-S338).

P. 1.i.004 Characterization of conditioned fear-induced c-Fos and phosphorylated CREB-positive cells in the basolateral amygdala by T. Izumi; T. Inoue; K. Konno; T. Yamaguchi; T. Yoshida; M. Watanabe; T. Koyama; M. Yoshioka (S338).

R1.h,010 Quality of life in young and professionally active men undergoing on-pump coronary artery bypass grafting by L.J. Krzych; A. Woznica; A. Pawlak; J. Skarysz; Z. Eysymontt; I. Krupka-Matuszczyk; A. Bochenek; M. Cisowski (S336).

P.1.h.009 Treatment of manic patients during hospitalisation – a retrospective chart review in 2004-2008: what has changed? by O. Yazici; O. Aydemir; S. Guloksuz; F. Akdeniz; C. Yenilmez; C. Akkaya; P. Cetinay; N. Ozpoyraz; A. Bozkurt; N. Kalkan Oguzhanoglu (S335).

P.1.h.004 Socio-demographic and clinical characteristics of elderly patients in acute psychiatric unit during ten year follow up by M. Serrano Vazquez; M.M. Serrano Carton; M.C. Serrano Carton; E. Bobadilla Perez (S332-S333).

P.1.h.003 Psychotropic medication consumption evaluation in hospitalized patients: comparison between 2004 and 2008 by B. Pascual Arce; A. Sicras-Mainar; M.C. Pérez-Navarro; L. García-Sánchez; N. Muro-Perea; M. Blanca-Tamayo (S332).

P.1.h.005 Incidence rate and prevalence of obsessive-compulsive disorder in treatment-seeking primary care patients by J.H. Veldhuis; T. Wohlfarth; J. Dieleman; J.G. Storosum; W. van den Brink; M.C.J.M. Sturkenboom; D.J.A.P. Denys (S333).

P.1.h.008 Prevalence of chronic obstructive pulmonary disease among those with serious mental illness by A. Karkanias; A. Kapsokaliva; G. Moussas; M. Lerikou; L. Stournara; G. Pavlakou; O. Anagnostopoulou (S334-S335).

P.1.i.008 Identifying patients with high pharmacy consumption by using the adjusted clinical groups in a primary care setting by A. Sicras-Mainar; R. Navarro-Artieda; S. Velasco-Velasco; J. Serrat-Tarrés; A. Prados; J. Estelrich (S340-S341).

P.1.i.017 Amelioration of affective disorders and quality of life in obstructive sleep apnea (OSA) patients following continuous positive airway pressure (CPAP) therapy by T.J. Paparrigopoulos; N.T. Economou; I. Koutsourelakis; H. Giannakopoulou; I. Kritikou; E. Perraki; F. Christidi; I. Zalonis; E. Vagiakis; C.R. Soldatos (S345-S346).

P.1.i.016 Serotonin, impulsivity and gender by D. Marazziti; S. Baroni; I. Másala; G. Consoli; M. Picchetti; F. Golia; M. Catena Dell'Osso; G. Giannaccini; L. Betti; A. Lucacchini (S345).

P.1.i.018 Clinical semantics, semiology and auto-evaluation. The challenging case of fatigue and sleepiness by D. Neu; D. Pieters; E. Morel; X. Montana; G. Hoffmann; P. Verbanck; R. Cluydts; P. Linkowski; O. Le Bon (S346-S347).

P.1.i.015 Serum folate, vitamin B12, and homocysteine in acute patients with schizophrenia, depression, or bipolar disorder by F.J. Trujillo; J.M. Raya; J. Monzón; T. Rodriguez-Martos; M. Salinas; T. Martin-Santos; M. Sanginés; M. Henry; A. Jiménez-Sosa; R. Gracia (S344-S345).

P.1.i.014 Serum levels of vitamin B12, folate, and homocysteine in patients with persistent suicidal ideation or suicide attempt by F.J. Trujillo; J.M. Raya; J. Monzón; T. Rodriguez-Martos; A. Renshaw; L. Morabito; M. Henry; R.M. Morales; A. Jiménez-Sosa; R. Gracia (S343-S344).

P.1.i.01l A standardisation of the Korean version of reaction inventory to measure anger by I.S. Chee; J.L. Kim; S.K. Wang; S.Y. Kim; Y.W. Cho (S342).

P.1.i.012 Treatment of insomnia in patients with schizophrenia by O. Dimova; V.F. Filovska; K.M. Kujundziska (S342-S343).

P.1.i.013 Neuropsychiatric drugs consumption: a pharmacoepidemiological study by M. Ponte; P.F. Garcia Merletti; E.L. Jurisic (S343).